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ABSTRACT
Celiac Disease (CD), gluten allergy (GA), and non-celiac gluten sensitivity (NCGS) represent a highly
varied disease grouping that affects individuals to varying degrees in response to the ingestion of certain
cereal proteins (wheat, barley, rye, and sometimes oats). Generally, epidemiologic data on food allergy
and intolerance is severely lacking; given current trends of under-diagnosis, prevalence of overt CD
alone is estimated at 1-2% of European populations.
There is a large and growing body of scientific literature that ascribes the complexity of various
gluten-sensitive symptomology to multiple developmental pathways. This complexity translates largely
in to delayed clinical diagnosis by medical professionals. Furthermore, public awareness of glutenaverse reactions as a serious medical condition remains low; there likely exists a sizable amount of the
population that displays symptoms but does not pursue a gluten free diet due to a lack of knowledge.
These delayed diagnoses result in an extremely decreased quality of life for those affected and for those
with undiagnosed CD, there exists an increased risk for the development of refractory celiac with fatal Tcell lymphoma. The goal here is two-fold: (1) to conduct an epidemiologic pilot survey geared toward
the characterization of contemporary paths to diagnosis of a small sample of individuals with CD, NCGS
and GA and (2) to use the results of this survey to make suggestions for decreasing time to diagnosis for
this widespread contemporary health issue.
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INTRODUCTION
Celiac Disease (CD), Non-Celiac Gluten Sensitivity (NCGS), and gluten allergy (GA) represent a complex
grouping of gluten-averse conditions that may be some of the most misunderstood, underdiagnosed,
and easily treated conditions within the United States (Fasano et al 2003). Celiac disease (CD) is an
immunogenetic disorder that affects multiple systems and displays a broad array of clinical
presentations ranging from gastrointestinal symptoms only (“classic” CD) to gynecological, neurological,
hematological, and many other non-gastrointestinal manifestations exclusively (“atypical”) (Dickey
2009). Diagnosis of CD has traditionally rested upon histological examination of the proximal
duodenum, wherein the presence of enteritis acts as the standard presence indicator. However, the
nature of this multisystem ailment actually suggests the existence of a CD- gradient (Kagnoff 2007) for
which allopathic diagnosis has been largely ineffective. For example, approximately 5% of persons with
CD are mistakenly diagnosed with irritable bowel syndrome (Sanders et al 2001). Serological testing
indicates that CD is prevalent among 1% of the world population. NCGS has only recently been
acknowledged by medical research as its own entity separate from CD (Sapone et al 2011), and has yet
to be universally acknowledged among physicians. Gluten allergy is more commonly diagnosed in
children and prevalence estimates are less than 0.4% (Venter and Arshad 2011). Onset of all three of
these conditions involves the ingestion of certain cereal proteins (glutens) and all are currently treated
with a gluten-free diet (GFD).
Unfortunately, the complexity of these conditions has translated largely in to delayed clinical
diagnosis by medical professionals. Furthermore, public awareness of gluten-averse reactions as a
serious medical condition remains low; there likely exists a sizable amount of the population that
displays symptoms but does not pursue a gluten free diet due to a lack of knowledge. These delayed
diagnoses result in an extremely decreased quality of life for those affected and as delayed diagnosis is
associated with an increased risk for the development of refractory conditions that do not respond to
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treatment with a gluten free diet and greatly increased risk for T-cell lymphoma (3-6x). Previous
research indicates that persons affected by CD in US often feel that their diagnosis was delayed (Green
et al 2001) (n=1612, most diagnosed at ages 40-50). Current data shows that average delay for CD
diagnosis in the United States is approximately 11 years (Fasano et al 2003). Such delays may reflect the
lack of information and relatively low importance of food allergies from general practitioners and some
internists (Gupta et al. 2008, 2009, 2010). As of yet, no one has characterized the delay in diagnosis for
NCGS, but it is likely longer than that of CD given that it is only recently recognized. The goal here is
two-fold: (1) to conduct an epidemiologic pilot survey geared toward the characterization of
contemporary paths to diagnosis of a small sample of individuals with CD, NCGS and GA and (2) to use
the results of this survey to make suggestions for decreasing time to diagnosis for this widespread
contemporary health issue.
Provided below is: (1) An immunology primer to familiarize the reader with the terms and
processes underlying immune system reactions; (2) an introduction to adverse food reactions including
classification and relevant terminology; (3) An overview of glutens and their role in disease; (4) an
overview of the gluten-averse conditions; and (5) and summary of the three gluten-averse conditions,
with special attention to CD and NCGS.
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IMMUNOLOGY PRIMER
The immune system is a widely distributed collection of tissue and cells that protect the body against
various pathogens (Kindt et al 2008). It is highly adaptable and most importantly can distinguish self
from non-self. It can be divided in to two major branches, adaptive and innate immunity. The innate
response is the primary boundary against invasion from pathogens. It is non-specific in that its
effectiveness does not rely on the precise recognition of pathogens. Instead, it seeks out generalized
invaders, distinguished by common genetic patterns that are common to many pathogens. The
adaptive immune system is a secondary line of defense. The key to its effectiveness is in the
development of an immunological memory that allows highly specialized defenses to be mobilized in
response to invaders, especially upon future encounters. Provided here is a basic overview of the
adaptive immune system alongside an introduction to the Gell and Coombs Hypersensitivity
Classification (1963). This physiological classification system can easily overlay the adverse food
reaction classification and provide biological rationale for the differential symptomology of various
allergic reactions.

THE ADAPTIVE IMMUNE SYSTEM
The adaptive process can be divided in to two major branches: humoral and cell-mediated immune
responses (Figure 1) (Widmaier et al 2008). Both subdivisions involve a similar initial sequence of events
that can be summarized as follows: the antigen encounters antigen-presenting cells that are
programmed to grab hold of it and initiate an immune response. Populations of helper T-cells
encounter the bound antigen and become activated such that they release cytokines (signals to other
cells). It is important to note that the divisions of the immune system are somewhat arbitrary and there
are many situations where these processes work together, often with overlapping function. Antigens
are any substances that can bind specifically to an antibody or TCR (described shortly) (Kindt et al 2008).
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Figure 1. The Humoral and Cell-Mediated Immune response pathways. The Humoral response
is focused on antibody production and is mediated by B-cells. Cell-mediated responses instead
involve the production of activated cytotoxic lymphocytes (CTLs) and do not involve antibodies.

Immune-Cell Typology
There are many types of cells within the immune system (leukocytes): granulocytes, lymphocytes,
mononuclear phagocytes, mast cells, and dendritic cells (Figure 2) (Kindt et al 2008). Each class of
leukocyte can be differentiated by size, function, and approximate lifespan and contains further
subclasses. The classification of immune cells is incredibly complex and only a few points and brief
descriptions are covered here, taken largely from Kindt et al (2008) and Widmaier et al (2006).
(1) Granulocytes are leukocytes that exhibit a particular pattern of staining that shows a
granular composition (Kindt et al 2008). The three subtypes are differentiated primarily by
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the shape of their nuclei. Neutrophils and Eosinophils are both phagocytes that migrate
from the blood stream in to damaged tissue. (Phagocytes are the immune cells that destroy
harmful foreign items by ingesting and digesting them.) Basophils do not possess
phagocytic function but instead play a role in cytokine (cell-signal) release in allergic
responses. Their function approximates that of mast cells but occurs within the blood
stream.
(2) Mast cells are a type of leukocyte that remains in their precursor form until they migrate
from the blood in to skin, connective tissues, mucosal epithelium and the like. Upon
migration they differentiate in to cells that carry a large amount of histamine and other
cytokines important for the inflammatory/allergic response.
(3) Monocytes are a type of mononuclear phagocyte that is able to migrate from the blood
stream into tissue and differentiate in to a macrophage with specialized function based on
its target tissue (e.g. intestinal macrophages exist in the gut, osteoclasts in bone).
(4) Dendritic cells (DCs) are a class of leukocytes named for their many long fingerlike
projections (similar to the dendrites of neuronal cells) (Satthaporn and Eremin 2001). Their
main function is in antigen-presentation (Kindt et al 2008). Generally, they are present in
areas of the body that have constant contact with the external world such as the skin and
the gastrointestinal tract. Once they encounter an antigen they migrate to nearby lymph
nodes and notify T- and B- cells.
(5) Lastly, lymphocytes are white blood cells of varying types produced in bone marrow that
circulate through both the blood (20-40% of white count) and lymph systems (99% of lymph
cell count). They can be divided in to three different types: B-cells, T-cells and Natural Killer
(NK) cells. Special attention will be given to these cells in the next paragraphs due to their
universal involvement in the initiatory stages of adaptive immune system responses.
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All of these immune cells are derived ultimately from a single type of progenitor cell within the bloodhematopoietic stem cells (HSCs) (Kindt et al 2008). All leukocytes discussed here undergo at least two
major type changes within their developmental trajectory. All ‘intermediate forms’ are only partially
differentiated toward their end character and some are termed ‘naïve’. For example, B-cells remain in a
naïve form until their first encounter with an antigen at which point they mature in to memory B-cells
(specific to the encountered antigen) able to produce antibodies. The timing and trajectory of HSC
development and all intermediate forms are tightly controlled by numerous regulatory networks so that
the appropriate type and amount of immune cells exist in the correct places at pertinent times in order
to provide maximum protection against various pathogens.
Leukocytes
Granulocytes
Neutrophils
Eosinophils
Basophils

Lymphocytes

B-Cells

T-Cells

Helper-T Cells

Cytotoxic T-Cells

Mast Cells
Natural Killer (NK)
Cells

Mononuclear
Phagocytes

Dendritic Cells

Monocytes
Macrophages

TH1, TH2, and TH17 subtypes

Figure 2: Major Leukocyte Subclasses.

B- and T- Cells
An understanding of B- and T-cell functionality is crucial for understanding the adaptive immune
response: B-cells have antigen-presenting capability (Kindt et al 2008). The B-cell surface receptor
responsible for binding the antigen is known as an antibody (Ab) or immunoglobulin (Ig). These
molecules (bound or free-roaming) are able to recognize and bind free-roaming antigens. Although
specific to the antigen, there exist different classes (isotypes) of immunoglobulins: IgA, IgG, IgE, IgD, and
IgM. These isotypes differ in location and function (see Table 1). Immunoglobulin A is of particular
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importance in adverse food reaction because it is the primary antibody released in the gastrointestinal
tract (Montiero et al 2010).

Antibody
Isotype
IgA

IgD
IgE

IgM

IgG

Location

Functions (some)

Mucosal areas (e.g.
digestive tract,
bronchus, urogenital
tract), breast milk,
saliva, tears.
Produced by B-cells
that occupy subepithelial tissue
(Montiero et al 2010)
Antigen receptor on
naïve B-cells.
Most IgE is bound to
mast cells and
basophils, some freeroaming
Expressed on B-cell
surfaces and also
secreted in free
roaming form

Able to activate the
complement system

Activate basophils and mast
cells
Bind allergens and signals for
histamine release from mast
cells and basophils
(inflammation)
Involved in early stages of cellmediated response (prior to IgG
response), can activate
complement pathway (most
effective)
Free roaming
Activate complement pathway,
calls in macrophages and
neutrophils, involved in
antibody dependent
cytotoxicity, Only antibody that
can cross placental barrier.
Table 1: The 5 Immunoglobulin isotype superfamilies.

% Total Serum

Number of
Subtypes

10-15%,
But comprises
70%+ of the Ig
found in external
secretions.

2

<1%

1

<<1%

1

5-10%

1

approximately
80%
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T-cells require further development once they arise from bone marrow and proceed to the thymus
gland in order to complete maturation (“T” is for thymus) (Kindt et al 2008). These T-cells do not have
antibodies as the B-cells do. Instead the surface receptors responsible for binding antigens are called Tcell receptors (TCR). T-cells are divided in to two types based on their particular TCRs: Helper-T cells
(TH) have CD4-type TCRs and cytotoxic-T cells (TC) have CD8-type TCRs. T-cells (via their TCRs) only
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recognize antigens that have already been bound by antigen-presenting cells (not free-roaming
antigens). A third type of T-cell exists; T-regulatory cells contain CD4 type TCRs but have other surface
proteins that make them functionally distinct. TH cells come in further subtypes: TH1, TH2, and TH17. TH1
cells are involved in cell-mediated immunity and TH2 cells are those that participate in the humoral
response. TH17 cells assist in inflammation. Activity of TH1 cells inhibits the activity of TH2 cells and vice
versa, in order to keep the differential pathways from operating at the same time (and keep responses
more specialized).

Cell-Signaling
The various cells of the immune system communicate with each other using specialized signals (Kindt et
al 2008): Cytokines are a broad category of biochemical signals that include the interleukins (ILs),
interferons (IFNs), and others (see Table 2 for some important examples). The large amount of signaling
allows tight regulation of the various immune processes. Cytokines may act to promote or inhibit and

Adaptive
Immunity

Innate Immunity

many are pro-inflammatory (Dinarello 2000).

Cytokine

Secreted by

IL-1

B cells, NK cells,
macrophages

IFN-α
IFN-β

Macrophages
Macrophages, dendritic
cells
Macrophages,
endothelial cells
Macrophages
Fibroblasts

IL-15

Phagocytic cells

IL-2

TH1

IFN-γ

TH1, TC, NK cells

TNF-β

TH1

TNF-α
IL-12
IL-6

Some Effects
Promotes development (maturation) of B-cells,
stimulates helper T-cells, activates NK cells, and
promotes inflammation
Inflammation, liver,
Cytotoxic T-cell differentiation, causes NK cells to
upregulate their IFN-γ and TNF-α production
Antibody secretion, differentiation of various B, T,
and plasma cells for immune response
NK activation, increases MHC I expression
NK activation, increases MHC I expression
NK activation, suppresses cell apoptosis, T-cell
regulatory roles
Promotes T-cell development
Promotes NK activation, TH1 development, increases
MHC expression (I and II)
Inhibits B-cell population expansion, inhibits
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IL-3
IL-4

TH1 and TH2, NK cells
TH2, mast cells,
macrophages

IL-5

TH2, mast cells

IL-10

TH2, macrophages

IL-13

TH2, B-cells

TGF-β
IL-18

T cells, macrophages
Macrophages

macrophage activity
Promotes histamine release from mast cells
Proliferation of T-cells, IgE synthesis from B cells,
development and expansion of B-cell populations
Differentiation of B-cells and IgA synthesis,
development of eosinophils
Stimulates macrophages to release cytokines,
activates B cells, inhibits TH1 cytokines, promotes TH2
production
Stimulates B-cell populations and inhibits TH1 and
macrophage cytokine production
Inhibits B-cell populations and macrophages
Promotes NK activity, increases production of IFN-γ

Table 2: Common cytokines of the immune system, their source and general effects.
Antigen-Presentation
Nearly all cells in the body are able to present antigens to helper-T cells and elicit an immune response
(Kindt et al 2008). T-cells only recognize antigens bound to very specific molecule types- those encoded
by the massive gene complex known as the Human Leukocyte Antigen (HLA). Proteins coded by this
complex can be subdivided in to two large groups: Major Histocompatibility Complexes I and II (MHC I
and II). MHC-I molecules are displayed by almost any nucleated cells in the body (non-immune) and can
be divided in to three subtypes: A, B, and C (in humans). These molecules are composed of an α chain
(coded by the MHC I) and a non-covalently associated β 2- macroglobulin chain. MHC-I molecules are
used in signaling cytotoxic-T cells. MHC-II proteins are displayed by antigen-presenting cells (APCs) that
include macrophages, dendritic cells, and B-cells. Some non-immune cells also express MHC-II
molecules- fibroblasts, pancreatic beta cells, certain endothelial cells are some examples. All MHC class
II proteins contain two chains (arms) (α and β) that physically assist in the binding and presentation of
antigens. These molecules exist in different sub-types (DM, DQ, DR, and DP in humans) and are used to
communicate with the helper-T cell populations.
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Cell-mediated Response
The cell-mediated response protects the body against pathogens that have slipped past the innate and
humoral defenses (present in the blood and lymph) and integrated themselves in to intracellular
environments. Cell-mediated mechanisms can recognize and eliminate self-cells that have been
infected and also cells that have undergone some sort of mutation (tumorous cells) (Figure 2, right
column).
Two signals are needed to activate this response (Kindt et al 2008). A non-immune cell
encounters an antigen and ingests it. The cell notifies the immune system that it has encountered an
invader by presenting the antigen on its cell surface to local TC cells using the MHC-I complex. APCs
encounter the same antigen and present it via MHC-II molecules to populations of passing TH1 cells.
These helper T cells become activated release cytokines that induce cytotoxic T cells (that have
encountered the MHC-I signals) to develop in to cytotoxic T lymphocytes (CTLs). CTLs eliminate any
‘altered’ self-cells that have encountered the antigen. The development of CTLs specific for the
pathogen takes time, which is why the cell-mediated response is ‘delayed’ onset and begins a few days
after initial infection.
Cytokines produced by TH1 cells include interferon-gamma (IFN-γ) and tumor necrosis factor beta (TNFβ) (Kindt et al 2008). Interferon-γ (IFN-γ) is responsible for the recruitment of macrophages (“big
eaters”) to the site of antigen encounter. Macrophages in turn signal for the up-regulation of MHC-II
complex expression, further TH1 production, and the inhibition of TH2 activity through the secretion of
IL-12 and IL-18. CTLs release their own set of signals which also include IFN-γ and TNF-β along with
various cytotoxins that assist the CTL in destroying the target infected self-cell.
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Humoral Response
The humoral response also involves TH cells, but only to aid in B-cell maturation (not to activate CTLs)
(Figure 2, left column) (Kindt et al 2008). This pathway is B-cell driven: B-cells encounter free-roaming
antigens, bind, and display the intruder such that TH2 cells can respond with cytokine production. The
cytokines released in this process signal back to the B-cells and promote them (B-cells) to develop their
antibody secreting abilities (B-cell maturation). The primary difference between the cell-mediated and
humoral responses is that antibody production is only involved in the humoral response (not the cellmediated response).
Antibody production cannot start without the appropriate signaling from TH2 cells (Kindt et al
2008). Cytokines released by TH2 cells include interleukins 4, 5, and 13. IL-13 and 4 are responsible for
encouraging the production of IgE and some IgG antibodies. IL-4 is also the key player in the promotion
of TH2 development as well as TH1 inhibition. IL-13 functions in the GI tract to increase mucus
production and muscle contraction. IL-5 activates eosinophils to assist in elimination of any helminthes
that have been bound by IgE. Cytokine signals used in the humoral and cell-mediated responses are
almost entirely non-overlapping (Table 2).
In humoral immunity, the newly produced free floating antibodies bind the relevant antigens
and mark them for removal from the body (Kindt et al 2008). To this end, merely binding antigens is not
enough and additional signaling is required. There are a few major effects that can be mediated by
signaling from antibodies: IgM (and most IgG) type antibodies can activate the complement system.
The complement is actually a portion of the innate system that can be brought in to play by the
adaptive immune system, when helpful. It is comprised of a few types of proteins that circulate
naturally in the blood as precursors to certain protein products. These proteins can do several things:
(1) they can promote a process of antigen removal called opsonization wherein macrophages and
neutrophils may be called in to phagocytose the harmful antigens. (2) Some of these complement
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proteins have the ability to puncture membranes of various invaders and can thus assist in antigen
removal by lysing (cutting open) the membranes of exogenous cells. (3) Some signals released by the
immunoglobulins summon immune cells with cytotoxic functionality- natural killer (NK) cells especially.
When NK cells arrive they are able to bind the free-floating antigen-specific antibody and use it to seek
out the offending antigen for destruction. This process is called antibody-dependent cell-mediated
cytoxicity (ADCC). IgE has additional functionality that allows it to activate mast cells, eosinophils and
basophils, all of which are important for the inflammatory response.
The humoral response differs depending on whether the antigen of interest has been previously
encountered or not (Kindt et al 2008). If the antigen is new to the system, a ‘primary’ response is
initiated. Antibodies produced by the first-time response are predominantly IgM and there is a focus on
development of mature B-cells that are sensitive to the new antigen. In a secondary response however,
preexisting populations of mature B-cells helps decrease response time greatly and their already
considerable numbers are able to elicit a larger response. The predominant antibody produced by a
secondary exposure is IgG. The development of antibodies against a particular antigen is termed
sensitization. An individual is considered ‘sensitized’ to a particular substance if they have antibodies
for it.
On a side note, NK cells are a nice example of the somewhat arbitrary nature of the divisions
between adaptive and innate immunity and also between the two subtypes of adaptive immunity. NK
cells are non-specific immune cells that can influence both the innate and adaptive responses. They can
release cytokines (IFN-gamma) that promote the activity of macrophages (innate response). NK
cytokines can also influence the development of Helper-T cells in to either TH1 or TH2 types. Lastly, the
use of antibodies by NK cells in a process called Antibody-Dependent Cytotoxicity (ADCC) shows NK cells
utilizing a product of the humoral response to carry out a function of cell-mediated immunity.
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Figure 3. Gut-associated lymphoid tissue (GALT).

THE GASTROINTESTINAL TRACT AND IMMUNE FUNCTION
The lymph tissue of the gut bears the greatest burden in protection of the body due to its constant
contact with the external environment. The antigenic load processed by gut-associated lymph tissue
(GALT) within a single day far exceeds that handled by the systemic immune system within the human
life time (Cochrane et al 2009). This gastrointestinal-associated lymph tissue (GALT) can be divided into
three general compartments (Figure 3): Peyer’s Patches, lamina propria, and intraepithelial spaces
(Macdonald and Monteleone 2005). Peyer’s Patches are the lymph nodes of the small intestine that
contain local populations of macrophages, B-cells, T-cells, and dendritic cells. The lamina propria is the
thin layer of connective tissue that lies beneath the epithelial layer that helps make up the mucosa of
the gut. It also houses the capillaries that supply blood to the small intestine. (The mucosa, or mucosal
layer, is comprised of the epithelial lining and the lamina propria.) The intraepithelial spaces are the
small pockets of space between the epithelial cells that contain the intraepithelial lymphocytes. Overall,
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the GI epithelium is responsible for nutrient absorption, barrier functionality, and the production of
various substances for digestion and protection (Shimizu 2010).

Commensal Bacteria
Immune function is closely tied to the commensal bacteria of the gut throughout the human lifespan
(Bjorksen 2004). At birth, the human gut is sterile. Within one week it is populated with various
bacteria and within three months bacterial populations are generally settled into symbiosis with the
gastrointestinal tract. The interactions involved are complex (Tanoue et al 2010). The commensals of
the gut help to train the immune system during its most formative period (Cebra et al 1998; Hooper
2001). HLA-DQ genetics have been shown to have an effect on the progression of gut colonization in
newborns (Sanchez et al 2011). A balance must be maintained throughout life through sustained barrier
function and immunological tolerance (Kraehenbuhl and Corbett 2004; Sanz and De Palma 2009).
Approximately 1014 bacteria (1 kg) live in an individual human small intestine alone, a number 10 times
larger than the number of cells in the human body. At least 500 species of resident bacteria have been
identified and this number is projected to be less than 50% of the species total (Guarner and Malagelada
2003). These collective bacterial colonies have been referred to as ‘the forgotten’ immune organ but
are beginning to receive more recognition for their role in human health and disease (O’hara and
Shanahan 2006). For example, Heijtz et al (2011) have discovered that gut microbiota play a role in
brain development that may predispose for various behavior later in life (anxiety included). Depression
is also known to develop from a combination of increased intestinal permeability and increased
translocation of commensal bacteria into the submucosa (Maes et al 2008).
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THE INFLAMMATORY RESPONSE
The inflammatory response is a series of events that is triggered when a pathogen makes it past the skin
and mucous membranes (where innate immunity is most active) (Kindt et al 2008). The response may
be immediate onset (acute) or chronic. The acute response is the body’s primary method of repair for
the initial stages of infection. Symptoms are easily identified: swelling, heat, pain, redness, and
depending on the degree of inflammation, loss of function. Vasodilation allows increased blood flow to
the site of infection. Vascular permeability is increased that allows fluid to accumulate in the area
(edema). Once this has occurred, various leukocytes are prompted to migrate from the nearby
bloodstream in to the infected area to assist in pathogen removal. These leukocytes also release
cytokines that amplify the response until the pathogen has been effectively neutralized and tissue repair
is complete.

HYPERSENSIVITY TYPOLOGY
Typically the immune response eliminates an antigen with minimal damage to the host’s tissue. The
mechanisms described above work together to bring about a targeted response that clears various
viruses, bacteria, parasites, and any other foreign particles that are encountered. However,
inappropriate immune system responses in some situations can cause injury or death (Kindt et al 2008).
These inappropriate and damaging immune responses are termed hypersensitivities, of which
there are 4 main types (Gell and Coombs 1963) (Table 3). For ease of comparison, the three conditions
relevant to this study are printed in bold-face type in the table. Of course, there are some disorders that
could fall under multiple categories or have not yet been characterized well enough to classify.
Remember, here the term ‘hypersensitivity’ is used more broadly than as defined by the NIAID (Boyce et
al 2010). This is because it is a classic categorization of allergy that long predates the recent NIAID
report; it is used universally in immunology and medical practice.
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An allergen is commonly described as anything that can cause an allergic reaction (Kindt et al
2008). Some have used the term more specifically to refer to any nonparasitic antigen capable of
bringing about a type 1 (anaphylactic) reaction. The NIAID describes food allergens as any component of
food that can induce an immune response (Boyce et al 2010). Here the latter definition will be used: any
antigen that elicits an adverse immune response is called an allergen.
Types 1, 2, and 3 hypersensitivities occur within the humoral response and involve an
‘immediate’ reaction of a sensitized immune system to the encounter of the allergen. These reactions
manifest within minutes to hours of exposure (Kindt et al 2008) and are distinguished by their
predominant mediators and corresponding effector molecules (discussed shortly). Type IV
hypersensitivity on the other hand occurs during cell-mediated immunity and is delayed onset (days)
Within each of these four categories, one can subdivide by source of the antigen. In some cases
the antigen is from outside the body (exogenous) and an allergy results; in other cases the body’s
immune system develops a memory for some part of the self and an autoimmune disorder develops.
All hypersensitivities denote ‘allergies’ because they involve an inappropriate immune response of some
kind, whether the antigen is exogenous or not. To describe an autoimmune disorder as an allergy is
technically correct given the definitions provided here. However, the differences in pathology
underlying these distinctive varieties of allergy are considerable and the distinction between general
allergy and autoimmune disorders should not be taken lightly. Here, ‘allergy’ and ‘autoimmune
disorder’ are used to distinguish the source of the antigen.
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Gell and Coombs
(1963)
Type I: IgEMediated/
Anaphylactic

Type II: Antibody
Dependent
Cytotoxicity

Type III: Immune
Complex Mediated

Type IV: Delayed
onset
hypersensitivity

Proximal Cause
Cross-linking of IgE on
mast cells causes
degranulation and
release of vasoactive
mediators
Antibodies are directed
against cell surface
antigens which cause
destruction through
activation of the
complement system or
ADCC
Antigen-antibody
complexes bring about
complement activation
and large scale
inflammatory response
(through influx of
neutrophils)
Sensitized helper-t cells
release cytokines that
activate cytotoxic cells or
macrophages that target
‘infected’ cells for
destruction.

Unclassified/Mixed Unknown/mixed

Mediators Source of Antigen
IgE

IgM or IgG

Foreign
Autoimmune

None

Foreign

Pernicious anemia
Rheumatic fever, Autoimmune
hemolytic anemia, Bullous
pemphigoid

Autoimmune
(cytotoxic)
Autoimmune

Graves' disease, Myasthenia
Gravis

Foreign

Reactive arthritis, Rheumatoid
arthritis, Serum sickness, Arthus
reaction

Autoimmune

Systemic lupus erythmatosus,
Sub-acute bacterial endocarditis

Foreign

Allergic contact-dermatitis,
Non-Celiac Gluten Sensitivity

Autoimmune

Type-1 diabetes, Hashimoto's
Thyroiditis, Guillian-Barre
Syndrome, Multiple Sclerosis

IgG

T-cells,
CTLs
especially

Unknown/
mixed

Some Example Conditions
Atopic dermatitis, Classic food
allergy (milk, egg, peanut,
wheat …)

Foreign
Autoimmune

Transplant rejection, Latex
allergy (1 and 4)
Sjogren's syndrome,
Autoimmune Hepatitis, Celiac
Disease (Types II and IV)

Table 3: Overview of Hypersensitivity Disorders. Note: Classification of NCGS is still in the works. The mechanisms
that underlie this condition are not yet fully elucidated (see Non-Celiac Gluten Sensitivity).
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TYPE I HYPERSENSITIVITY
Type I hypersensitivity is the most studied of the four types- likely because it involves rapid onset
symptoms and tends to be a concern more often in childhood (Sampson 1999). In this process, IgE
antibodies produced by the humoral response bind tightly to mast cells and basophils (a process called
sensitization, mentioned earlier). Upon second exposure to the allergen, an environment is created
wherein bound antigens encourage the cross-linking of the antigen-specific IgE of various mast cells.
(Cross-linking is where an antigen binds two different antibodies simultaneously on the same mast cell).
This cross-linking in turn triggers the mast cells to degranulate 1 (disintegrate) and release a large
amount of chemical signals in to their immediate environment (see Table 4). Some of these signals are
released directly from the mast cells (primary action) and some are a downstream effect of the primary
signals (secondary actions). These signals include vasoactive mediators (e.g. histamine) that are able to
cause smooth muscle contraction, vasodilation, and increase vascular permeability. In other words, IgE
invokes an inflammatory response. Cytokines are released that may promote systemic anaphylaxis and
further increase the production of IgE. Degranulation cytokines include: IL-3, IL-4, IL-5, IL-6, IL-10, IL-13,
GM-CSF, TNF-α, and others. Some of these cytokines function to bring in other specialized immune cells
including eosinophils and neutrophils (chemotactic function).

1

Crosslinking is one of 5 recognized triggers of mast cell degranulation (Kindt et al 2008).
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Action
Primary

Mediator
Histamine, heparin

Effect
Increase vascular permeability, smooth muscle contraction

Primary

Proteases

Secondary
Secondary

Platelet activating
factor
Leukotrienes

Increase mucus production from bronchial tubes, degrade blood
vessel basement membrane
Platelet aggregation and degranulation

Secondary
Secondary
Secondary

Prostaglandins
Bradykinins
Various cytokines

Increase vascular permeability; pulmonary muscle contraction,
broncho-constriction
Vasodilation, platelet aggregation, pulmonary muscle contraction
Increase vascular permeability, smooth muscle contraction
Increase IgE production (IL-4 and IL-13), systemic anaphylaxis (IL-1
and TNF-α)

TABLE 4. Mediators released by the degranulation of mast cells in a type 1 reaction (primary)
and those formed secondary to the release of the primary mediators.
Normally, the IgE response is used to fight parasitic infections, particularly helminthes (Kindt et al 2008).
However, some genetically predisposed persons have a condition that allows them to develop these
reactions toward various natural environmental components (Boyce et al 2010). This condition is called
atopy or atopic syndrome. These individuals often have 10x the normal amount of naturally circulating
IgE (Kindt et al 2008:374). Common symptoms of localized type 1 hypersensitivity reactions include
atopic dermatitis (a type of eczema), urticaria (hives), asthmatic attacks, allergic rhinitis, vomiting and
diarrhea (Boyce et al 2010). All of these may occur in response to ingested food allergens. Crossreactivity is also a concern in the development of type 1 hypersensitivity (Breiteneder and Mills 2006).

TYPE II HYPERSENSITIVITY
In Type II hypersensitivity, antibodies interact with membrane bound ‘antigens’ and either (1) activate
the complement system or (2) initiate antibody dependent cell-mediated cytotoxicity (ADCC). The error
occurs when there is a failure of tolerance to a naturally occurring element in the body or when a true
antigen happens to resemble a naturally occurring cell surface molecule. In this second case antibodies
are made against the antigen but they are also able to cross react with the naturally occurring element
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and an inappropriate response is elicited. Macrophages recognize and bind these antigens and present
them to B-cells so that antibody production can begin. In both cases, any cell to display the offending
antigen is marked for destruction. Common examples of this category include autoimmune hemolytic
anemia, Graves’ Disease, and pernicious anemia.

TYPE III HYPERSENSIVITITY
In Type III hypersensitivity, antigen-antibody complexes (IgM or IgG) cluster in unnaturally large
amounts in various tissues (Kindt et al 2008). Normally these complexes are marked for destruction
however the buildup of these clusters can activate the complement pathway such that a massive
inflammatory response is brought about and a large amount of neutrophils are brought in to assist in
the phagocytosis of the perceived offender. Neutrophils further amplify the inflammatory signals by
releasing their own cytokines. Most commonly this clustering occurs in blood vessel walls, joints, parts
of the kidney and the cerebrospinal fluid compartments of the brain (choroid plexus). Type III reactions
can be localized or generalized depending on the location of the complex deposits. Disease examples
include lupus erythematous and rheumatoid arthritis.

TYPE IV HYPERSENSIVITITY
Type IV hypersensitivities occur during the cell-mediated immune response and are often referred to as
Delayed-Type Hypersensitivity (DTH) (Kindt et al 2008). The cell-mediated immune process proceeds
normally (as described above) but is in reaction to an inappropriate stimulus. Key components to DTH
include (of course) the time delay until onset, as well as the recruitment of macrophages (instead of
neutrophils). Cell-mediated immunity is an important defense against intracellular antigens; various
bacteria, fungi, parasites, and viruses travel via intracellular pathways. Type I diabetes and allergic
contact dermatitis are examples of this category.
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ADVERSE FOOD REACTIONS
Celiac Disease, wheat allergy, and non-celiac gluten sensitivity are all clinically different conditions with
distinctive pathophysiology. Commonalities exist between these conditions: all are triggered by the
ingestion of gluten, and a gluten free diet (GFD) is the only current treatment in all cases. These
common features, coupled with a lack of reliable diagnostic criteria have led to extensive confusion
among both medical professionals and the general public regarding these various conditions (Boyce et al
2010). Clinical presentation of these conditions can be similar, but this is not the rule. The distinction
between conditions remains important primarily because differential symptomology can aid health
professionals (and individuals) in diagnosis. A better understanding of these conditions is therefore
preceded by a working understanding of adverse food reaction classification (allergy, intolerance and
the like). Adverse food reactions include any clinically abnormal reaction to a given food (Anderson
1991). Provided here is an overview of adverse food reactions with special attention to gluten-averse
conditions, as well as definitions and clarifications on relevant terminology.
Below is a table of the three known classifications of gluten-averse conditions (Table 5) - Celiac
Disease (CD), Gluten Allergy (GA), and Non-Celiac Gluten Sensitivity (NCGS). These are the names that
will be used throughout this project, and were chosen because they are in line with the definitions of
allergy and intolerance as put forth by the NIAID (Boyce et al 2010). Synonyms are listed to the far right,
some of which are to be avoided for reasons listed below. Here we will explore two separate but largely
overlapping classification systems under which these conditions may be sorted- one put forth by the
NIAID to classify adverse food reactions (Boyce et al 2010), and also the classic typology for adverse
immune system reactions described in the hypersensitivity section (Gell and Coombs 1963).
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Adverse Food Reaction
Classification

Hypersensitivity
Type

Onset of
Symptoms

Celiac Disease
(CD)

Non-IgE Mediated
Humoral Immune
Response

Auto-Immune
Disorder/
Mixed
Classification
(Types II and IV)

Variable (some
immediate,
some delayed
symptoms)

Gluten Allergy
(GA)

IgE-Mediated Humoral
Immune Response

“Classic” Allergy/
Type I

Immediate
Onset (within
minutes to
hours)

Wheat Allergy,
Gluten
intolerance

Allergy/
Type IV

Delayed Onset
(within hours to
days)

Gluten
sensitivity*
Gluten
Intolerance

Name

Non- Celiac
Gluten
Sensitivity
(NCGS)

Cell-Mediated Immune
Response

Other Names
(some improper)
Celiac Sprue,
Sprue, nontropical Sprue,
Gluten sensitive
enteropathy
(GSE), Gluten
intolerance

Condition is
undocumented
Intolerance
N/A
None
in medical
literature
Table 5. Gluten-averse conditions, including differences in classification and alternative
terminology. Terms shown in italics are other names that are used improperly to refer to the
condition listed. Non-italicized terms in the ‘other names’ column are true synonyms. *Gluten
sensitivity has been used by some to refer to any and all gluten-averse reactions.

Gluten
Intolerance

CLASSIFICATION
Adverse food reactions can be broadly divided into those that involve the immune system and those
that do not (see Figure 4). This primary division is illustrative of the differences between food allergy
and food intolerance (Anderson et al 1991; Ortolani et al 2006). In food allergy, the adaptive immune
system responds reproducibly whenever an individual is exposed to the food allergen (Boyce et al 2010;
Sicherer and Sampson 2010). In contrast, the adverse reaction generated from food intolerance occurs
for non-immune related reasons (Anderson 1986). For example, a person may be lactose intolerant
because their body does not produce sufficient amounts of lactase to aid in digestion. There exists a
third large category (not shown) that includes secondary sensitivities where an individual may have an
adverse reaction to a given food due to the effects of some other condition (e.g. drug-induced
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sensitivities) (Taylor 2001). Wheat allergy and celiac disease both involve the immune system and are
classified here under the allergy category. Note: CD is an autoimmune disorder, the pathophysiology of
which relates directly to the ingestion of gluten (food). However, it is not a ‘food allergy’ in the same
sense as wheat allergy. The reaction is food related, but the inappropriate immune response involved is
against a naturally existing (endogenous) protein in the body (see Celiac Disease Pathophysiology
section).
The entire immune-mediated category of adverse food reaction pertains to responses from
various parts of the adaptive immune system. Within immune-mediated adverse food reactions there
are those that are directed by the humoral immune response (immediate) and those that involve cellmediated immunity (delayed). Immediate responses can be further divided based on the primary
antibody class involved. “True” allergies involve an IgE-mediated response, sensitization and reaction
upon future encounters to the allergen (Venter and Arshad 2011). However, sensitization, or the
presence of IgE specific for the food allergen, does not completely predict a negative reaction upon
second exposure (Boyce et al 2010). A positive correlation exists between level of IgE and chances of
negative reaction and some researchers have argued for a predictive cutoff point (Boyce et al 2011).
Thus far, no cutoff has been established. The basic physiology of allergy and the responses mentioned
here will be covered in the upcoming section on adaptive immune system. In any case, allergy as a
classification still encompasses any immune-mediated adverse reaction to food.
Adverse food reaction classification can be overlaid with the Gell and Coombs (1963)
classification scheme for hypersensitivity to help further illustrate the underlying pathophysiology of
immune-mediated reactions (refer again to Figure 4). IgE-mediated reactions are entirely synonymous
with a type I hypersensitivity. Both Type II and type III hypersensitivities are non-IgE mediated. All cellmediated (delayed onset) adverse food reactions fall under the type IV hypersensitivity category.
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Adverse Food Reaction
Immune mediated

Non-immune Mediated

(food allergy and celiac disease)

(food intolerances)

Adaptive Humoral Response
Immediate hypersensitivity
Delayed
Hypersensitivity
IgE
Mediated

Non-IgE
Mediated

(eg. acute
urtiaria, oral
allergy
syndrome,
gluten
allergy)

(eg. food
protein
induced
enteropathy,
celiac
disease)

(type 1
hypersens.)

(types 2, 3
hypersens.)

Cell Mediated
Mixed IgE and
Non IgEMediated
(eg. eosinophilic
gastroenteritis)

Metabolic
(eg lactose
intolerance)

Pharmacologic
(eg caffeine)

Toxic
(eg
scombroid
fish toxin)

(eg allergic
contact
dermatitis, nonceliac gluten
sensitivity)
(type 4
hypersens.)

Figure 4. Classification of Adverse Reactions to Food based on Pathophysiology with
corresponding Gell and Coombs Hypersensitivity Classification (1963) (adapted from Boyce et al
2010).

TERMINOLOGY: DEFINITIONS AND CLARIFICATIONS
The various gluten-averse conditions have been described many different ways (see Table 5) and current
terminology-usage is confusing for all. The creation and use of standardized terminology is paramount
to clearing up the confusion over these three gluten-averse conditions. Provided here are some
definitions and clarifications aimed at standardizing the terminology for gluten-averse conditions:
(1) The term hypersensitivity is sometimes used synonymously with allergy, and sometimes as
a broader term to include food intolerances. The National Institute of Allergy and Infectious
Disease (NIAID) Guidelines Report uses the term only in reference to IgE-mediated adverse
reactions that take place within the gastrointestinal tract. Here, we will use the term more
broadly to refer to any immune-mediated adverse reaction, as is consistent with the
immunological terminology of the Gell and Coombs Classification System (1963), which long

Other/
Idiopathic/
Undefined
(eg. sulfites)
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predates the recent NIAID report. Food intolerances can be referred to as non-allergic
hypersensitivities (Johansson et al 2001).
(2) Tolerance has two different definitions, provided by two different spheres of authority.
According to the NIAID, tolerance is a condition where a person no longer exhibits symptoms of
food allergy- either through outgrowing the allergy naturally or through therapy. If a person has
never had an allergy to a particular allergen, they are not said to have ‘tolerance’ for the
allergen. However, in general immunologic terms, tolerance is also a state of protection of the
self against its own immune system (Kindt et al 2008). Here we will use the second and more
general definition of tolerance. In either case, intolerance is not an appropriate term to use as
an opposite for tolerance. Intolerance is still only defined as a non-immune mediated adverse
food reaction. The common root is not considered meaningful for these two terms. In the case
of our second tolerance definition, the reverse situation is referred to as ‘failed tolerance’.
(3) The terms ‘gluten intolerance’ and ‘gluten sensitivity’ are both used in a wide variety of
circumstances, contributing greatly to the confusion about the different types of gluten-averse
reactions. Some people use these terms as catch-all classifications for any adverse gluten
reaction (allergy and celiac disease). Some have used these terms as labels to refer more
specifically to the delayed reaction to wheat, characteristic of the cell-mediated immune
response (e.g. Food Intol.org 2011). In any case, gluten ‘intolerance’ is not an ‘intolerance’ as
officially classified by the NIAID; it is a misnomer. A non-immune mediated adverse reaction to
glutens has not been documented in medical literature. The classification is correct only as far
as differentiating it from a ‘true’ allergy which induces an immediate response (within hours).
However, the response is immune-related nonetheless and still falls under the category of
allergy. Here, the term Non-Celiac Gluten Sensitivity (NCGS) is chosen to refer to this form of
delayed-- onset adverse gluten reaction.
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(4) Gluten Intolerance may exist as a condition (non-immune adverse reaction) although it has
yet to be described in medical literature. Currently, ‘gluten intolerance’ as described in
published literature involves an immune component and is thusly not an ‘intolerance’ but an
allergy. For example, “Gluten intolerance is a common, immunologically mediated disorder with
a widely variable clinical presentation that affects genetically predisposed subjects” (Bardella et
al 2005:15).

It seems reasonable that a term be chosen to represent the spectrum of gluten-averse conditions.
Gluten sensitivity is the best candidate of those in current use. However, there are some downsides to
its adoption as the catchall term. (1) Non-Celiac Gluten Sensitivity would sound as if it is defined in
opposition to Celiac Gluten Sensitivity, implying that NCGS would also include wheat allergy. (2) Gluten
sensitivity as a term is already used by some to describe the third condition (NCGS) and those using the
term would need to re-clarify their descriptions as NCGS. It could be argued that due to its use in a
variety of definitions that it should be abandoned on the whole and an entirely new term should be
created. No matter the adopted broad term, a large scale adjustment will need to take place regarding
usage and it will need to be recognized that publications prior to the approximate change must be read
carefully. Here, a new term ‘gluten-averse condition’ is created to be used as the broad scale term that
includes CD, GA, and NCGS.
Inconsistencies in terminology are at least partly reflective of the inconsistencies in adverse food
reactions more generally (Gupta et al 2007). Misuse continues despite the implementation of
standardized terminology on adverse food reaction from the World Allergy Organization beginning in
2001, many definitions of which predate the 1980s (Johansson et al 2001; Johansson et al 2004) (see
Zopf et al 2009 as an example). Publicly available information is wrought with inaccuracies, which
undoubtedly contributes to the spread of misinformation, and in turn a large amount of missed
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diagnoses for people attempting to self-diagnose. A quick internet search for ‘celiac disease’, ‘wheat
allergy’ and ‘intolerance’ turned up the following examples of misuse (see Table 6).

Source
National Institute
for Allergy and
Infectious Disease 2

Improper Terminology Use
“Gluten intolerance: Gluten intolerance is associated
with celiac disease, also called gluten-sensitive
enteropathy. This disease develops when the immune
system responds abnormally to gluten. This abnormal
response does not involve IgE antibody and is not
considered a food allergy.”
“What is the difference between Wheat Allergy and
Wheat Intolerance? For clarity they are NOT the same
thing: Wheat Allergy is a severe sudden onset allergic
reaction to a certain protein component of wheat. That
is, it's an auto-immune response of the body. … It can
cause life-threatening responses in allergic
people….HOWEVER, most people who speak of wheat
allergy are really referring to Wheat intolerance caused
by Gluten …Wheat Intolerance is when you have difficulty
digesting wheat, which may seem less important. It is a
slower onset but certainly involves the immune system…”

Comment
The NIAID, whose standards
are used in describing allergy
and intolerance, uses the
term intolerance to describe
an immune-mediated
reaction (allergy)
FoodIntol.org mistakenly
described wheat allergy as an
autoimmune condition.
(Celiac Disease is the
autoimmune condition.)
They also use the term
‘gluten intolerance’ to refer
to an immune-mediated
reaction.

American
Association of
Retired Persons
(AARP) 4

“Celiac disease is an inherited, autoimmune disease in
which the lining of the small intestine is damaged from
eating gluten and other proteins found in wheat, barley,
rye, and possibly oats. Sprue; Nontropical sprue; Gluten
intolerance; Gluten-sensitive enteropathy”

The AARP lists gluten
intolerance as a synonym for
Celiac Disease.

ExitAllergy.com 5

“What Is Gluten Allergy? The digestive disorder coeliac
disease (gluten allergy) scars the lining of the small
intestine preventing the absorption of nutrients. Gluten
allergy symptoms manifest as gastrointestinal distress of
all forms.”
“Common food intolerance conditions that are often
mistaken for food allergies include: ….Celiac disease. This

Exit Allergy.com uses Celiac
Disease and Gluten allergy as
synonyms.

Food Intol.org 3

MayoClinic.com 6

2

The Mayo Clinic incorrectly
places Celiac Disease under

http://www.niaid.nih.gov/TOPICS/FOODALLERGY/UNDERSTANDING/Pages/foodIntolerance.aspx
http://www.foodintol.com/wheat.asp
4
http://healthtools.aarp.org/adamcontent/celiac-disease-sprue?CMP=KNC-360I-GOOGLEHEA&HBX_PK=gluten_intolerance&utm_source=Google&utm_medium=cpc&utm_term=gluten%2Bintol
erance&utm_campaign=G_Diseases%2Band%2BConditions&360cid=SI_148893851_6495451981_1
5
http://www.exitallergy.com/allergy-articles/diagnosing-gluten-allergy.php
6
http://www.mayoclinic.com/health/food-allergy/AN01109
3
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chronic digestive condition is triggered by eating gluten,
a protein found in bread, pasta, cookies, and many other
foods containing wheat, barley or rye. Signs and
symptoms of celiac disease include diarrhea, abdominal
pain and bloating. While celiac disease involves an
immune system response, it's a more complex food
reaction than a food allergy.”

the intolerance category.

Table 6: Examples of wide-spread misuse of terminology for the gluten-averse conditions.

These points on terminology illustrate nicely the considerable amount of confusion on part of both the
public and health professionals when it comes to describing gluten-averse responses and adverse food
reaction in general. In particular, misuse of the term ‘intolerance’ is widespread even within peerreviewed research publications, sources that should be considered both reliable and authoritative. For
example, Granzotto et al (2009) describe Celiac Disease as “characterized by intolerance to gluten” (p
1513). Freeman et al (2011) and many others can be quoted identically.
Summarily, standardized terminology has yet to be mass-applied and one must keep this in
mind when reading publications that involve wheat allergy, celiac disease, and adverse gluten-reactions,
as well as allergy and intolerance, in general. All attempts have been made here to utilize the official
terminology set forth by the NIAID in their 2010 publication (Boyce et al 2010).

FOOD ALLERGY OVERVIEW
The importance of adverse food reaction as a medical condition can be best illustrated by a social
contextualization of impact. An epidemiologic overview of food allergy is provided prior to discussing
the three gluten-averse conditions. Celiac Disease will be discussed in further detail within the next
section.
Although food allergy represents a significant health concern, especially among children, basic
epidemiologic information is lacking (Lack 2008). Over 170 foods have been documented to cause IgE-
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mediated allergic reactions (Boyce et al 2010). The most common ones (“Big Eight”) include: wheat,
shellfish, eggs, fish, peanuts, milk, tree nuts, and soybeans (Taylor 2001) and account for over 90% of all
adverse food reactions (Branum et al 2008). Food allergy occurs almost exclusively in response to
ingested proteins (Radauer et al 2008) and as mentioned above can cause either immediate immune
response (minutes to hours) or delayed hypersensitive reaction (24 hours or later) (Taylor 2001).
Adverse reactions range from mild depression and gastrointestinal discomfort to anaphylactic shock and
death (Boyce et al 2011). Despite the clear potential to benefit, there continues to be an absence of
universal diagnostic criteria (Venter and Arshad 2011).
Estimates of incidence and prevalence are highly varied and any synthesis and comparison of
such estimates is currently impossible. A recent meta-analysis by Rona et al (2007) summarizes the
findings of 51 studies- food allergy (self-reported) varies between 3-35% of the total population
(regardless of location, but largely dominated by Western groups). Clinically confirmed food allergy by
(oral food challenge) estimates between 1-10.8% prevalence, based on 6 studies. Conservative
estimates currently indicate that 6-8% of children and 4% adults have food allergies and/or intolerances
(Bangash and Bahna, 2005; Burks and Ballmer-Weber, 2006; Sicherer and Sampson, 2006) although this
cannot be verified. Public knowledge on adverse food reactions is dominated by a tendency for people
to classify any adverse reaction as food allergy and tends to result in an over-reporting of allergy
incidence: self-diagnosed food allergy may be as much as 10 times higher than the true value attainable
by medical testing (Venter and Arshad 2011). Thus, a range of possibility exists for the true prevalence
of food allergy and the measures of central tendency remain elusive.
Provided here is a summary table of food allergy prevalence estimates per allergen (Table 7).
Note that these range estimates are derived from studies of varying methodology and it is not possible
to report fairly anything more than a range. Additionally, the division between adults and children (age
18) is not necessarily biologically meaningful for the purposes of allergy development. Countries
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represented in these estimates are predominantly Western groups- outside of the Western world
estimates of allergy prevalence are even more sparse.

ALLERGEN ALLERGY PREVALENCE
Children
Age
Milk
0.2-2.5%
under 18
Egg
0.2-5.0%
under 18
Wheat
0-0.4%
under 15
Fish
0-0.2%
under 18
Shellfish
0-1.8%
under 18
Peanut
Tree nut

Adults
0.1-1.1%
0.2-1.3%
0-1.4%
0.1-0.6%
0-2.5%
0.06-5.9%

Age
18-60
18-60
18-60
18-60
18-60
1 - 85.

Countries Included
France, UK, US, Denmark, China, Israel
France, UK, US, Denmark, China, Australia
US, Australia
US, Canada, UK, Denmark, Germany, Australia
US, Canada, UK, Denmark, Germany, France
US, Canada, France, Germany, Sweden, UK, Australia,
Israel, Singapore, Philippines,
0.03-8.5% 1-65.
US, Canada, France, Germany, Sweden, UK, Australia,
Israel, Singapore, Philippines,
Table 7. Prevalence ranges per food allergen, per age group, and associated countries included
in estimate. Prevalence here is based on sensitization and reaction. (Info from Venter and
Arshad 2011).

Traditionally, food allergy has been a concern mostly in early childhood- a large amount of effort has
focused on childhood allergy and its potential ‘remission’. One study shows annual incidence of
clinically diagnosed food allergy decreasing from 4.7% to 1.2% from the ages 1-2 through ages 5.6 years
of age (Schnabel et al 2010). Children affected by food allergy are more likely (2x-4x) to suffer from
related conditions including asthma, eczema, and other respiratory allergy (Branum et al 2008). It is
generally accepted that the neonatal period developmentally important in terms of tolerance
(Brandtzaeg 2002), a time that corresponds to the development of a healthy commensal flora in the gut
begins shortly after birth (Indrio et al 2011).
There is some evidence that food allergy prevalence varies by geographic region and population,
although this cannot be confirmed without consistent diagnostic criteria (Freeman 2010). Any variation
that does exist cross-culturally is likely the result of differential human genetic and epigenetic
backgrounds (Tjon et al 2010) and also a function of cultural patterns for the breeding, storage, use and
preparation of preferred foods (Shek and Lee 2006).
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Unfortunately, delayed onset (cell-mediated) allergic reactions have not received as much
attention as their immediate onset counterparts- which are much easier to diagnose (Jyonouchi 2008).
Non-IgE mediated reactions are typically not life-threatening: Generally, delayed reactions are often
more mild, appear days post-contact/ingestion, and are typically diagnosed later in life (among adults).
“True”, or anaphylactic, allergic reactions have received the bulk of epidemiologic and medical research
thus far and unfortunately there is very little to no information on which foods might be most commonly
responsible for cell-mediated (delayed) allergic response (Venter and Arshad 2011).

Increasing Prevalence of Food Allergy
Current research points almost universally to an increase in food allergy prevalence (all allergens) within
recent decades, even after controlling for diagnostic improvement (Bjorksten 2004; Cochrane et al
2009). For example, the U.S. Department of Health and Human Services reports that between 2004 and
2006, hospitalizations due to food allergy for individuals under the age of 18 increased from
approximately 2,000 to 10,000 (Branum et al 2008). Food allergy rose by 18% among children under age
18 from 1997 to 2007. In 2007 alone 3 million food allergy diagnoses were made among children (under
age 18). This information is taken from the National Hospital Discharge Survey (NHDS); any food
allergies diagnosed by parents in the home in which children were not hospitalized are not included in
this estimate.
The apparent universal rise in allergy, coupled with increased knowledge of immune
development and regulation, has skewed much research from questions of individual pathogenesis
toward why lack of affect among all individuals (Bjorksten 2004). As of 2011, the hygiene hypothesis is
the forerunner for best explanation of increasing allergy rates (See Hygiene Hypothesis). Less popular
theories include the Dietary Fat Hypothesis, Antioxidant Hypothesis and the Vitamin D Hypotheses (both
increased and decreased) (see Lack et al 2008 for a review).
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HYGIENE HYPOTHESIS
The hygiene hypothesis was proposed by Strachan (1987) to account for the apparent increase in allergy
over the past century. He suggests that improved hygiene and interest in cleanliness have decreased
the occurrence of infection and microbial insult in children and thereby increased the incidence of
atopic diseases. This claim originated largely from the observation that the children of farmers have a
much lower incidence of allergy, and those of academic parents exhibit allergy more often (Ring et al
2004). Indeed there is substantial evidence to support the theory that a lack of immunological training
early in life may predispose to allergy (Kalliomaki and Isolauri 2002). Immunologically it is claimed that
early exposure to various pathogens (infection, parasites, vaccinations) skews the TH1/TH2 responses to
favor TH1 and thereby protect against IgE-mediated allergy development by down-regulating B cells
from class switching to IgE production (Schaub et al 2006). Currently, the theory does not satisfy all
conditions and circumstances and has met with mixed results in research (see Ring et al 2004). It is
likely that the hypothesis will undergo further revision but still stands to synthesize the findings of many
epidemiological studies (Linneberg 2008).

GLUTEN OVERVIEW
Proximal activation of CD, GA, and NCGS involve first-most the dietary intake of certain cereal grainswheat, rye, or barley (and sometimes oats) (Freeman 2010). Each of these grains contains seed storage
proteins that are responsible for adverse food reactions. There exist four major classes of seed storage
proteins: albumins, globulins, prolamins and glutelins (Kagnoff et al 2007). Of the seed storage protein
groups (Figure 5), prolamins contain the largest amount of known allergens to humans (Radauer et al
2007). Members of the wheat genus (Triticum) are known to contain prolamin- and glutelin- family
proteins, termed gliadins and glutenins, respectively. Rye, barley and oats contain the prolamins secalin,
hordein, and avenin respectively.
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The list of known allergens occur almost entirely in a small subset of known protein families- of
the 9318 currently recognized protein families, only 2% contain known allergens (Breiteneder 2008). Of
those that do, most family members are non-allergenic- prolamins are an exception. All prolamins are
characterized by a high proline and glutamine content (relative to other amino acids) and it is this high
proline content that makes them difficult to digest (Shan et al 2005). Glutens are the only dietary
proteins that seem to largely escape digestion by the gastrointestinal proteases (e.g. trypsin,
chymotrypsin, and pepsin) and tend to gather in the small intestine (Hausch et al 2002).
Glutens (Latin for “glue”) are peptide composites of prolamins and glutelins that reside naturally
in the endosperm of grass related proteins and are also the components responsible for the rising and
structuring of dough in bread-making. Wheat gluten (gliadin and glutenin combined) comprise 80% of
the protein content of wheat seeds (Anjum et al 2007). In the three known gluten-averse conditions,
persons can be hypersensitive to the prolamin or glutelin content of grains although glutenin (wheat
glutelin) is the most common allergen. There are several subcategories of gliadins based on various
biochemical properties (electrophoretic mobility and isoelectric focusing): α, β, γ, and ω-gliadins (Wieser
et al 2008).
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Triticum Genus
(Wheat)
Secale genus
(Rye)

Triticeae Tribe

Pooideae
Subfamily

Gramineae Family

Bambusoideae
Subfamily

Panicoideae
Subfamily

Hordeum genus
(Barley)

Aveneae Tribe

Avena Genus
(Oats)

Oryzeae Tribe

Oryza genus
(Rice)

Andropogoneae
Tribe (Maize,
Sorghum)
Paniceae Tribe
(Millet)

Figure 5. Taxonomy of Dietary Grains (adapted from Kagnoff et al 2007)

GLUTENS AS PATHOGENS
Glutens have been referred to as “non-replicative” pathogens (Bethune and Khosla 2008) because of
their ability to induce disease. They are known to have adverse effects on the human digestive tract,
regardless of genetic predisposition to CD (Drago et al 2006). A 2010 study by Biesiekierski et al utilized
a double-blind randomized placebo-controlled setup to assess the effects of gluten on a group of
healthy individuals prescreened for an absence of celiac disease (n=35). Both groups were assigned a
gluten-free diet for 6 weeks and were also given 2 bread slices and one muffin per day. One group
received their assigned baked goods with gluten and the other without (placebo). Those who received
the gluten-containing food reported significantly different symptoms within a week of the trial:
increased pain (p=0.016), bloating (p=0.031), and tiredness (p=0.001).
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Zonulin-Signaling
The results of Bisiekierski et al (2010) might be explained by the fact that gliadin is largely recognized to
increase permeability of the gut through the up-regulation of zonulin (Clemente et al 2003; Drago et al
2006; Lammers et al 2008). Zonulin is the only known reversible mediator of gut permeability- more
specifically of the tight junctions that help form the barrier function of gut endothelial cells (Tripathi et
al 2009).
Endothelial cells are key regulators of the body’s internal environment; they make up the layers
of the skin and line the GI and respiratory tracts, providing a barrier whose selective permeability
dictates the transport/migration of various solutes and metabolites in to the body and also protects
against invasion by various pathogens. Similar function is ascribed to the tight junctions (TJs) that bind
these epithelial cells to one another (Koch and Nusrat 2009). Physically, these junctions (also known as
zonula occludens) are anastomoses of scaffolding multi-protein complexes that anchor cytoskeletal
elements (actin) between cells via cytoplasmic elements and the inter-cellular binding of many
extracellular loops (Schulzke and Fromm 2009). TJs serve two larger goals: a ‘barrier function’ wherein
they regulate paracellular flux of materials and also a ‘fence function’ that keeps various membrane
proteins in the appropriate places (Sawada et al 2003). The nature of this system allows for regulation
of tightness (permeability) and some channel formation through intra- and inter-cellular signaling.
Proper function of this protein network is paramount to the avoidance of numerous disease states
including inflammatory bowel disease, irritable bowel syndrome, food allergy, liver disease, type II
diabetes and other auto-immune disorders, as well as many more (Groschwitz and Hogan 2009; Sawada
et al 2003).
Zonula occludens toxin (Zot) was first isolated by Fasano et al (1991) from the bacterium Vibrio
Cholerae. Its ability to reversibly disassemble tight junctions through the polymerization of actin
immediately prompted the search for a eukaryotic analogue. In 2000, Wang et al reported the discovery
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of human zonulin. The benefit of such a natural modulator is evident in the context of host-pathogen
interaction: In the presence of bacterial invasion, it is advantageous to loosen tight junctions such that
there is an efflux of water in to the intestinal lumen, and a flushing of pathogens from the system
(Asmar et al 2002). However, this increased permeability is not without risk: the greater the increases in
permeability, the larger the molecules are that can potentially pass through and interact the internal
environment (including gut-associated lymphoid tissue) (Drago et al 2006; Fasano and Shea-Donohue
2005).

Immune System Effects
Not all glutens are created equal (Bateman et al 2004). Chains of varying lengths appear to interact
differently with the immune system (Camarca et al 2009; Shan et al 2002). Several glutens (gliadins) are
shown to be active contributors to CD (and potentially NCGS) (Hausch et al 2002). Gliadins type-α, ω
and γ in particular seem to have the greatest stimulatory effect of T-cells (Camarca et al 2009). The αgliadin 33-mer and p31-43 peptide fragments appear to be the most resistant to breakdown by tissue
transglutaminase (mentioned in CD pathogenesis section) and thus the most pathogenic of the glutens
(Jabri and Sollid 2006; Mazumdar et al 2010; Shan et al 2002; Thomas et al 2006).
There is some evidence that glutens may contribute to the development of autoimmune disease
through a lowering of immune response thresholds (Nikulina et al 2004a). Dendritic cells of healthy
mice exposed to chymotrypsin-treated gluten are stimulated to mature and upregulate production of
MHC-II proteins and also to increases DC production of certain cytokines such as IL-1β, which is an
important effector molecule of the inflammatory response. All observed effects were dose-dependent.
Dendritic cells are especially concentrated in gut associated lymph tissue and are of primary importance
in the induction of IgA responses (Rescigno and Di Sabatino 2009). Additionally, Horiguchi et al (2005)
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reports a significant increase in NK activity in a small group of healthy persons when given wheatcontaining foods (n=9, p<0.05), although no mechanism is suggested.

GLUTEN-AVERSE CONDITIONS
GLUTEN/WHEAT ALLERGY
Gluten Allergy (GA) is one of the most common allergies worldwide (Venter and Arshad 2011) (see Food
Allergy Overview). It is an IgE-mediated (Type I) humoral immune response to ingested glutens (Boyce
et al 2010). Symptoms are those of a ‘classic’ allergic reaction and may include gastrointestinal and/or
cutaneous (skin) reactions. Gastrointestinal symptoms consist of vomiting, reflux, abdominal pain, and
diarrhea. Cutaneous reactions may display as hives, angioedema, swelling of various tissues (e.g. hands,
face, abdominal organs, and upper airway), and various forms of eczema. In severe cases, a person may
go in to anaphylactic shock, which can be fatal if not treated quickly. Symptoms are similar to those
listed but occur in extremes and are often accompanied by anxiety, difficulty
breathing/swallowing/talking, and heart palpitations.
Gluten Allergy is more often diagnosed in childhood as are many IgE mediated hypersensitivities
(Scibilia et al 2006). Additionally, timing of initial exposure appears to play a role in risk for gluten
allergy development (Poole et al 2010). Children exposed to cereals after 6 months of age are more
likely to develop GA than those exposed prior to 6 months of age (n=1612, p=0.025)

CELIAC DISEASE
Celiac Disease is an autoimmune disorder that likely falls under multiple categories of the Gell and
Coombs (1963) Hypersensitivity Classification (Types 2 and 4). It has a strong genetic component, highly
varied symptomology, and often occurs in conjunction with other medical conditions, autoimmune
disorders in particular (Abadie et al 2011). Many researchers have attempted to characterize the non-
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genetic factors that precipitate its development: breast-feeding (Guandalini et al 2007), infection
(Fasano 2002; Mahon et al 1991, Plot and Amital 2008), intestinal dysbiosis (De Palma et al 2008; De
Palma et al 2010; Di Cagno et al 2009), increased intestinal permeability (Abadie et al 2011; Bjarnason
and Takeuchi 2009; Drago et al 2006) have all been considered. None of these suffices as a universal
explanation and it is possible that development of CD should be considered on an individual level.
Diagnosis of celiac disease is largely settled upon histological examination of the small intestine,
antibody testing, and genetic screening (Kagnoff et al 2007). However, these methods are known to
result in false negatives (histology) and false positives (antibodies and genetics) if not interpreted
correctly, respectively (see Caja et al 2001; Tjon et al 2010). Below is a summary of CD epidemiology,
current information on pathophysiology, hypersensitivity classification, genetic predisposition, a brief
review of some potential non-genetic developmental factors, and a mockup of current known symptoms
and comorbid conditions.

Epidemiology
Epidemiologic information of CD has traditionally focused on the marked prevalence in populations of
European descent (Cataldo et al 2007; Tack et al 2010). As with allergy, estimates of epidemiology are
plagued with varied testing criteria and comparison of results between studies is difficult.
Until the 1970s worldwide prevalence of CD was estimated at only 0.03% (Tack et al 2010). As
of 2011, the consensus is that CD occurs in approximately 1% of adult populations worldwide (0.5-1.26%
95%CI) with the remaining exception of Japan (Dube et al 2005). Estimates vary somewhat by region
(Table 8): Barada et al (2010) summarize epidemiological data from Middle East and Northern African
populations (1950-2008). Data includes studies where diagnosis was confirmed using both serological
tests and histological examination. Estimated prevalence for these regions falls between 0.14% in low
risk populations to 44% in high risk populations. Here, low risk groups are healthy blood donors (mostly
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men) and high risk populations are groups with type II diabetes, thyroid issues or chronic malabsorption
issues. Shahbazkhani et al (2003) report a 1 in 166 prevalence of histologically confirmed CD in a group
of health Iranian blood donors. Remes-Troche et al (2006) report 2.6% potential prevalence of CD in a
group of healthy blood donors based on positive tTGA-IgA results (n=683, 68% men). Sood et al (2006)
reports that 1 in 310 school age children (3-17 years) tested positive for CD based on serology and
histology (n=4347) (see also Ramakrisha et al 2011). For yet unclear reasons, the Saharawi group of
North Africa has the highest confirmed prevalence of CD by intestinal biopsy worldwide (Catassi et al
1999; Ratsch and Catassi 2001; Teresi et al 2010). Reported CD is still fairly absent from Japan, and
other Far East countries (Freeman 2010) although there is some evidence that it may be present in
China (Jiang et al 2009). Wu et al (2010) report a 2.6% prevalence in a high risk (type II diabetes or
irritable bowel syndrome) prescreened group in China (n=78). Prevalence in the United States is
estimated at 1:133 for low risk groups in the US (Fasano et al 2003).

Area
North Africa (Egypt,
Tunisia, Libya, Algeria)

Europe
(Czechoslovakia,
Estonia, Finland,
Hungary, Ireland, Italy,
Norway, Portugal,
Spain, Sweden,
Switzerland,
Netherlands, United
Kingdom)
India
Middle East (Turkey,
Iran, Israel, Jordan,

Prevalence
0.14%-0.53% in “low risk” populations (mostly
healthy men blood donors),

Source
Barada et al 2010

2.6-44% in high risk populations (persons with type II
diabetes, thyroiditis or chronic malabsorption issues)

Barada et al 2010

5.6% in the Saharawi
1 in 99 Finnish school children

Catassi et al
1999; Teresi et al
2010
Maki et al 2003

2.4% Finland, 0.3% Germany, 0.7% Italy, adults ages
30-64

Mustalahti et al
2010

1:262 (Norway) – 1:85 (Hungary)

Cataldo et al
2007

1 in 310 school children (~0.3%)
0.33%-0.96% in “low risk” populations (mostly
healthy men blood donors)

Sood et al 2006
Barada et al 2010
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Kuwait, Lebanon, Saudi
Arabia, Iraq)
Mexico

2.45-19% in high risk populations (persons with type
II diabetes, thyroiditis or chronic malabsorption
issues)
2.6% in a group of healthy blood donors

United States

1:133 in healthy adults

Remes-Troche et
al 2006
Fasano et al
2003b

Table 8: CD prevalence estimates based on geographic region.

Diagnoses of CD are made at any age (Fernandez et al 2010). The bulk of cases are detected either in
early childhood or ages 40-50 (Dube et al 2005). Adult diagnoses favor women at approximately age 40
and men at approximately age 50. Prevalence among children worldwide is 0.31%-0.9% (Hoffenberg et
al 2003). Diagnosis in children more commonly isolates ‘typical’ CD presentation (Koluglu et al 2009).
Up to 20% of patients are over age 60 at time of diagnosis (Saez 2006) and most of these people display
the ‘non-classic’ phenotype with predominantly extra-intestinal manifestation or more subtle
gastrointestinal symptoms (see Symptomology) (Fasano et al 2003; Nejad et al 2009; Vilppula et al
2008). Vilppula et al (2009) demonstrate an increasing prevalence of CD in the elderly in Finland from
2002-2005.
CD is more common in females (F:M= 1.8:1), a fact mostly attributed to HLA-DQ2 inheritance as
a sex-linked trait from father to daughter (Khashan et al 2010; Megiorni et al 2008). Other non-HLA risk
alleles may have a sex-linked bias and contribute to this difference but none has been described in the
literature as of 2011. Tack et al (2010) has noted that immune-regulation also has a hormonal
component that might play a role in differential distribution of CD between men and women.
Interestingly, the CD sex ratio reverses for diagnoses in persons over the age of 60 (Green et al 2001).
Decker et al (2010) describe birth method as a potential risk factor for CD development. CD is
more likely to develop in children delivered by Cesarean section than in healthy controls (p=0.014). Due
to its genetic component, family members of CD-affected individuals are at higher risk for CD.
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Concordance between monozygotic twins is 80%; Dizogotic twin concordance is only 11% (Nistico et al
2006). Risk for CD in first degree relatives of CD patients is 1:22 and 1:39 for second degree relatives
(Fasano et al 2003). Hogberg et al (2003b) reports risk among 1st degree relative at 8.3%.
Celiac Disease is on the rise worldwide- a fact that is not entirely accounted for per improved
diagnostics (Catassi et al 2010; Lohi et al 2007; Rubio-Tapia et al 2009; Tack et al 2010). Is likely that
recent socio-cultural influences (since the 1970s) are key factors in this trend (see Non-Genetic Risk
Factors and Hygiene Hypothesis).

Pathophysiology and Classification
Celiac Disease has been somewhat difficult to classify because it involves components of the innate
immune system (the complement) as well as humoral and cell-mediated adaptive responses (Abadie et
al 2011). Some have described Celiac Disease as an intestinal inflammatory disease (Atkins and Furuta
2010; Tjon et al 2010) but the most current consensus is that CD more closely resembles a T-cell
mediated organ-specific autoimmune disorder (Abadie et al 2011). Ingested glutens that traverse the
gut lining are met with a naturally occurring enzyme called tissue transglutaminase (tTG) (also known as
TG2) (Figure 6) (Dieterich et al 1997; Elli et al 2009). Tissue transglutaminase exists largely in an inactive
intracellular form that is released when its containing cell is damaged (Siegel et al 2008). It plays a role
in breaking down glutens in a process called deamidation. Gorgun et al (2009) report that tTG is
overexpressed in the mucosa of untreated CD. More specifically, the process changes non-charged
glutamines into negatively charged glutamic acids (Dekking et al 2007). Per evolutionary chance this
modification creates a molecule (a deamidated gluten or DAG) that is preferentially bound by APCs
possessing a certain form of HLA-DQ2 or HLA-DQ8 molecule (Bethune and Khosla 2008). (The presence
of HLA-DQ2 or –DQ8 molecules represents the largest genetic risk factor of CD development). The high
affinity between deamidated gluten and tissue transglutaminase creates a situation where T-cells may
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develop memory for either part of the DAG-tTG complex. T-cells can then alert B-cells to produce
antibodies for the bound antigen. When the immune system begins developing antibodies for tTG (antitTG), an autoimmune disorder has developed and the individual can be classified as having Celiac
Disease (Table 3). CD is the only autoimmune disorder for which the auto-antigen is known (Ferguson et
al 2993). Antibodies produced against tTG and deamidated gluten (DAG) include IgA and IgG- classes
(Caja et al 2011). This particular component of CD pathophysiology qualifies it for partial classification
as type II hypersensitivity. In short, a self-perpetuating loop emerged: The presentation of glutens leads
to the release of IFN-γ by TH1, TC and NK cells. IFN-γ upregulates expression of MHC-II molecules (HLADQ2 and –DQ8 included) which in turn increase presentation of gluten peptides to TH1 populations. A
secondary loop begins when tissue is damaged and tTG is further released. An increase in tTG increases
the amount of deamidated glutens present which will in turn increase HLA-DQ presentation and thus
the T-cell response.
Additionally, the involvement of CTLs and NK cells to attack ‘infected’ tissue qualify CD for type
IV hypersensitivity classification (Anderson 1991). One hallmark of CD is the broad population
expansion of intraepithelial lymphocytes (IELs) (Abadie et al 2011). Intraepithelial lymphocytes are the
various lymphocytes positioned within the outer mucosal epithelial layers of the GI and reproductive
tracts (Kindt et al 2008) that conduct immunosurveillance of the local epithelium. Most IELs are T-cells
of various types. (Note: Below this mucosal layer is another layer called the lamina propria that contains
mostly B cells, active helper-T cells, and macrophages.) IELs are different from other lymphocytes in
that they release cytokines and attempt to destroy their targets immediately without need of priming.
In other words, there is no difference between the naïve and activated forms. One of the most clinically
dangerous aspects of Celiac Disease is the apparent destruction of absorptive surface of the small
intestine resulting from this cell-mediated process. The small intestine is lined with villi (fingerlike
projections) that increase the surface area dedicated to nutrient absorption. In most cases of untreated
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CD, this lining is destroyed (villous atrophy and crypt hyperplasia). TC IELs with a certain type of NK
activating cell receptor (TCR-αβ+) have been linked to the destruction of the intestinal epithelial cells
(Green et al 2003; Kutlu et al 1993). These particular receptors are thought to function in lowering
activation thresholds for T-cells under various stresses (Bauer et al 1999). Another sub-type of TC cell,
TCR-γδ+ cells, is sometimes used as a marker for determining latent CD (Kaukinen et al 2007) (see
Diagnosis). Epithelial cells that have come in to contact with the gluten or contain membrane bound
tTG are marked for destruction because they are seen as infected. This destruction of the small
intestine continues as long as glutens are ingested. Myrsky et al (2009) add that there is evidence of
vascular remodeling in conjunction with proximal bowel damage.

Figure 6. Antibody Production in Celiac Disease.
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There is evidence that celiac patients also have autoantibodies for more than just tTG, although the
symptomological implications of this have yet to be fully elaborated (Alaedini and Green 2008) (see
Symptomology). These autoantibodies have received less attention in the literature because the
presence of anti-tTG is the only known autoantigen to coincide with the acute onset of CD. Nonetheless
researchers have somewhat variably reported autoantigens against a slew of other molecules:
transglutaminase 3 (Lindfors et al 2011), cytoskeletal actin (Clemente et al 2000), ganglioside (Volta et al
2006), collagen, calreticulin, zonulin (Fasano 2000), factor XIII, synapsin I, cardiolipin, enolase α, and ATP
synthase β chain (see Alaedini and Green 2008 for a review). It seems likely that further research will
confirm that these additional autoantibodies to be associated with particular clinical manifestations of
symptoms.
The pathogenesis of CD is far from fully elaborated. There is an apparent disconnect between
outward gluten-averse symptoms and the presence of villous atrophy (Kaukinen et al 1998).
Metabonomic analyses indicate that the physiological conditions of gluten-averse symptomology may
precede observable destruction of the small intestine: Bertini et al (2009) characterized the metabolic
signature of CD through proton mass spectroscopy. Serological analyses show that CD patients had
lower levels of various amino acids, lipids, pyruvate and choline compared with healthy controls
(p<0.01). Also, CD patients had elevated glucose (blood sugar) and 3-hydroxybutric acid, a protein
created in the liver for energy use under conditions of low blood glucose (p<0.01). Urine analyses
showed lower levels of mannitol, glutamate, glutamine and pyrimidines as well as higher levels of
indoxyl sulfate (IS), choline, glycine, acetoacetate, uracil, mHPPA, and PAG (p<0.05). These serological
results describe alterations of glucose metabolism, possibly through reduced glucose uptake by cells or
errors in process of glycolysis. Urinalyses indicate differences in microbiota populations and an increase
in gut permeability in CD relative to healthy controls (see Environmental Risk Factors). Bernini et al
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(2010) has shown that this metabolic signature is similar between ‘potential’ and overt CD. Likely
metabolic changes are in place before the onset of small intestinal destruction.
Interleukin-15 is also known to play a role in CD pathogenesis (Meresse et al 2004; Tang et al
2009): Harris et al (2010) report that monocytes from healthy individuals differentiated to macrophages
through IL-15 exposure and subsequently produced IL-1β, IL-6, IL-15, IL-23, and TNF-α and also activated
Th1 and Th17 cells. Monocytes from CD patients required a lessened exposure to IL-15 to produce the
same effect in response to gliadin exposure, perhaps indicating lowered threshold activation.
Manavalan et al (2010) confirms that persons with active CD and those being treated with a gluten free
diet (with positive serology) both exhibit elevated levels of IL1β, IL-6, IL-8 and various Th2 cytokines.
Meresse et al (2006) has shown that IL-15 may play a role in reprogramming CTLs into NK-like cells in CD
and up-regulating the expression of MHC-I molecules. A comparison of IL-18 between active CD and
healthy control showed mature IL-18 only to be found in CD patients (Salvati et al 2002), implying
altered activity of TH1 cells. The overexpression of tTG in CD may be due to an accumulation of
particular gliadin fragments (p31-43 fragments) in the lysosomes of endothelial cells that trigger the
epithelial cells to upregulate their tTG expression (Luciani et al 2010.

1. Destruction of lining of small intestine (crypt hyperplasia/villous atrophy).
2. Autoantibodies against tissue transglutaminase.
3. Population expansion of CTLs in mucosal lining (cytotoxic IELs) through
lymphocytosis.
4. Overexpression of tTG in mucosal tissue.
5. Altered commensal bacteria in gut.
6. Altered IL-15 production alters TH1 and TH17 responses to gluten.
Table 9. Summary Physiological Features of Untreated Celiac Disease
The clinically significant findings of CD pathogenesis are summarized in Table 9. As of 2011, CD
pathogenesis is best understood in a multiple hit model (Abadie et al 2011) wherein a secondary event is
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needed to trigger development past predisposing genetics and physiology (Ferguson et al 1993). In
addition to genetic preconditions, some form of intestinal stress must trigger IEL activation.

Genetic Components
CD has a strong genetic component. Numerous studies have attempted to characterize the genetic
profile of CD, utilizing genome wide association studies, mapping and linkage analysis (Hunt and van
Heel 2009). Approximately 90% of those diagnosed with CD carry the HLA-DQ2 haplotype, and the rest
have the DQ8 haplotype (Dubois et al 2010; Sollid and Lie 2005) (6.23 odds ratio, Dubois et al 2010).
Approximately 0.5% of persons affected by CD have neither haplotype (Cassinotti et al 2009). The
presence of haplotypes also provides information on predisposition; CD associated HLA haplotypes
appear to exhibit a dosage effect (Hernandez-Charro et al 2008). Persons who are homozygous for HLADQ2 are five times more likely to develop CD than those who are heterozygous. This homozygosity is
also associated with the development of severe complications such as T-cell lymphoma (Cassinotti et al
2009).
Human leukocyte antigen- DQ are receptors found on antigen presenting cells (APCs) that are
one of the many types of MHC class II molecules discussed earlier; they bind particular antigens and in
turn expose them to helper T cells, which illicit the appropriate immune response (Jabri and Sollid 2006).
DQs themselves are heterodimers (αβ); they are comprised of two chains that are genetically coded by
the HLA-DQA1 and –DQB1 alleles found on chromosome 6 (6p21.32). At present there are four known
haplotypes associated with this heterodimer, two of which are considered to be high risk for CD
(Cassinotti et al 2009). HLA-DQ2 (DQA*0501, DQB*0201, termed HLA-DQ2.5) and HLA-DQ* (DQA*03,
DQB*0302)… are the more specific descriptions. Individuals homozygous for the HLA-DQ2.5 risk alleles
are five times more likely to develop CD than those who are homozygous (Mearin et al 1983). The dose
effect of the HLA-DQ2.5 risk alleles is directly related to the magnitude of T-cell response (Vader et al
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2003). More recently Thomas et al (2009) failed to replicate the correlation of severity of CD symptoms
with HLA-DQ2.5 based on endomysial antibody (EMA) testing (see Diagnosis).
The presence of HLA-DQ risk alleles appears to be required for CD development but is still not a
good predictor - approximately 30% of the world population possesses these risk variants (Hunt et al
2008). The HLA-DQ2 risk allele is found more often in Western Europe, Northern and Western Africa,
the Middle East and Central Asia, and the –DQ8 allele found slightly more often in Northern Europe and
Central America (Cummins et al 2009).
Additionally, the genetic portrait of CD is not as simple as a bimolecular system. As of 2010,
over 60 non-HLA risk minor loci have been identified in various genome-wide association studies
(Amundsen et al 2010; Babron et al 2003; Forabosco et al 2009; Garner et al 2009; Greco et al 1998;
Heap and van Heel 2009; Hunt et al 2008). Total risk explained by these non-HLA loci is estimated at 5%
(Dubois et al 2010). Castellanos-Rubio et al (2010) have grouped many of these non-HLA loci according
to physiological pathway and have found clusters pertaining to cell-cell communication, intracellular
signaling, the ubiquitin-proteasome system, and regulation of the cell cycle, particularly apoptosis (cell
death). One notable loci is CTLA4: there is some evidence to suggest that presence of two adenines at
this locus is correlated with the presence of ‘silent’ CD (Gudjonsdottir et al 2009; Zhernakova et al 2005).

Environmental Factors
Environmental risk factors are of important consideration in pathogenesis given that genetics only
account for approximately 30% of CD-risk (Freeman 2010; Greco et al 2002). Secondary precipitating
factors may include: Intestinal dysbiosis (De Palma et al 2010), infection (Fasano 2002), and leaky gut
(Groschwitz et al 2009). Ultimately, each of these risk factors involves a barrier defect of the intestinal
epithelium, either temporary or long-term. This is because the first and foremost step in CD
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pathogenesis is the inappropriate perambulation of the gut lining by glutens. The barrier function must
be compromised to allow contact between IELs and glutens.

Immune Development and Intestinal Dysbiosis
De Palma et al (2010) confirm a shift in the population structure of gut commensal bacteria toward an
increase in gram-negative relative to gram-positive bacteria in untreated children with CD compared
with controls and CD-affected children on long-term gluten free diets (p=0.006 and p=0.045,
respectively) (Table 10). Several of the bacterial populations measured were significantly decreased in
children with untreated CD and one was increased. CD children treated with a gluten free diet showed
values intermediate to those of the untreated CD and control groups in all cases of difference. Further
analysis for presence of IgA showed that healthy controls had significantly higher IgA-coated
Bacteroides-Prevotella compared with untreated CD (p=0.014). No difference in IgA coating of
Bifidobacterium was observed between groups. Accordingly De Palma et al (2010) suggest a barrier
defect present in CD. It is possible that reductions of favorable gram-positive populations in CD allow
population expansion of gram-negative bacteria within the gut. On another note, children with allergies
exhibit a delay in their development of Bifidobacterium and Lactobacillus (Kalliomaki and Isolauri 2003).
Bifidobacteria are known to inhibit the inflammatory response that would otherwise be induced by
gliadin exposure (Laparra and Sanz 2010).
Bacterium
Bifidobacterium
C. histolyticum
C. lituseburense
F. prausnitzii
Bacteroides-Prevotella
E.coli
Staphylococcus
LactobaccillusEnterococcus

Untreated
CD
Much lower
Lower
Lower
Lower
Greater
Same
Same
Same

Significance
p=0.009
P=0.031
P=0.024
P=0.045
P=0.033
Not significant
Not significant
Not significant
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Table 10. Intestinal Dysbiosis in children with Celiac Disease compared with healthy controls (from
De Palma et al 2010).
Other research has supports that intestinal dysbiosis is present in CD although there are variations on
the particular bacterium involved: Di Cagno et al (2009) report lactobacilli strains to be greatly reduced
in CD. Ashorn et al (2009) highlight the presence of anti-Saccharomyces cerevisiae antibodies (ASCA)
present in celiac patients that decrease with gluten free diet. Nadal et al (2007) describe a much
reduced ratio of Lactobacillus-Bifidobacterium to Bacteroides-E.Coli in patients with CD (treated or
untreated). They also found an overabundance of gram-negative bacteria relative to positive in CD
patients. Sanz et al (2007) found that children with CD generally displayed a higher diversity of gut
bacteria compared with healthy controls. However, Bifidobacteria species were more diverse in healthy
controls. Similarly, Sanchez et al (2008) describe a reduced diversity of gut microbiota in CD children
and also an increase in virulence factors for gut microbiota present. Papp et al (2009) found antimicrobial antibodies to be significantly higher in untreated CD than treated CD or healthy controls for
antichitobioside (ACCA), antimannobioside (AMCA) and ASCA. Population structure of gut microbiota
has been shown to influence intestinal permeability (Cinova et al 2011). Rubio-Tapia et al (2009b)
report the presence of small intestine bacterial overgrowth (SIBO) in approximately 9.3% of CD patients,
treated or untreated. Schippa et al (2010) detected a greater amount of Bacteroides vulgatus and E. coli
in children with CD relative to controls and a generally higher biodiversity.
Breastfeeding appears to be protective against Celiac Disease (Guandalini et al 2007; Ivarsson et
al 2002). Risk for celiac disease is greatly reduced for children for whom dietary gluten is introduced
while still breastfeeding (Norris et al 2005). Also, gluten intermittently introduced with breastfeeding
appears to correlate with the development of the non-classic CD phenotype (Guandalini 2007; Silano et
al 2010). Breastfeeding affects the colonization of the gut by commensal bacteria- it is proposed that it
reduces the risk of celiac disease through the encouragement of healthy immune development, which
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depends on healthy colonization of the gut (Sanz et al 2008). Indeed, differences in the microflora of
the newborn gut have been observed at one week of age between healthy and allergic infants, prior to
any clinical manifestation of hypersensitivity (Bjorksten 2004). Rationale for the development of a
disease state from intestinal dysbiosis ultimately derives from the hygiene hypothesis (Kalliomaki and
Isolauri 2002).

Infection
Autoimmune diseases have been long observed to precipitate with infection (Plot and Amital 2008). The
most commonly reported infectious associations of CD are Hepatitis C Virus (HCV) and Adenovirus 12
(Ad12). Published reports of CD association with Ad12 are limited (Kagnoff et al 1987; Mahon et al
1991). Mantzaris et al (1990) has suggested this to be a result of cross-reactivity between Ad12 and αgliadin. More currently, HCV has been acknowledged for its CD association (Fine et al 2001; Ruggeri et al
2008). Hernandez et al (2007) did not find a reliable association between HCV infection and CD onset
but notes that HCV may still be a precipitating factor in individual cases. Additionally, exposures to
neonatal infections appear to be a reasonably good predictor of CD risk (OR 1.52) (Sandberg-Bennich et
al 2007). Stene et al (2006) describe a possible increased risk for CD development following recurring
rotavirus infection in early childhood. Notably, some researchers have suggested that certain infections
may be protective against CD development (Plot et al 2009). Evidence of past infection (via antibody
test) by rubella, cytomegalovirus (CMV) and Epstein-Barr Virus were all lower in Celiac patients as
compared with healthy controls (p<0.05, p<0.01, p<0.01).

Leaky Gut
Increased intestinal permeability (IP), also known as ‘Leaky Gut’, is the most heavily investigated nongenetic factor in CD-risk to date (Abadie et al 2001; Bjarnason and Takeuchi 2009; Drago et al 2006;
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Fasano 2011; Fasano and Shea-Donohue 2005; and many others). The reasons for this are two-fold:
There is evidence that Celiac patients exhibit altered expression of epithelial junction proteins for tight
junction formation in the small intestine (Ciccocioppo et al 2006) and the intestinal barrier function is
known to be affected by a multitude of sources- exogenous factors, cytokines, and lymphocytes
(Groschwitz 2009; Menard et al 2010). Currently increased intestinal permeability is largely
acknowledged as a precondition for the development of CD (Visser et al 2009). Interleukins 4, 10, and
13 are known to alter gut permeability (Groschwitz 2009). T-cells modulate permeability through IFN-γ
and TNF-α. Exogenous factors of IP include alcohol (Purohit et al 2008), heat stress (Yang et al 2006),
non-steroidal anti-inflammatory drugs (NSAIDS) (Bjarnason and Takeuchi 2009; Kefalakes et al 2009;
Kerckhoffs et al 2009), pathogens (Vibrio cholera, E. Coli, and Clostridium perfringens) (Fasano 1991,
Muza-Moons et al 2004, and Fujita et al 2000, respectively), stress (Gareau 2008), anything that might
cause low grade inflammation (Peuhkuri et al 2010), and others.
Altered zonulin signaling and increased permeability have been prime targets of CD genetic
research (Monsuur et al 2005). So far, there are no genetic risk associations for up-regulated zonulin
signaling in celiac disease, although the physiological relationship is observed (Wolters et al 2010):
Drago et al (2006) exposed intestinal cell monolayers to gliadin and found that zonulin release was
greater than in cells taken from CD than from a non-CD control group (0.67±.013 ng/mg and .02 ±.01,
respectively, p=.01). CD patient cell groups showed elevated mucosal zonulin release at 5 minutes postincubation that remained for one hour. The control group cells showed a slight increase in luminal
secretion of zonulin that maxed at 15 minutes and subsided completely within half an hour. The same
study found that chronic exposure of gliadin was able to decrease expression of key tight junction
proteins (ZO-1 and occludin). Intestinal permeability issues in CD may be entirely environmentally
mediated given that intestinal permeability appears to revert to normal parameters upon treatment
with gluten-free diet (Duerkson et al 2005; Duerkson et al 2010).
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A SPECTRUM OF SYMPTOMOLOGY
CD has a complex phenotype that is commonly split into ‘classic’ and ‘non-classic/atypical’, based on
longstanding cultural construction by clinicians (Brown 1921; Nejad et al 2009; Torres et al 2007). Some
groups have suggested that the ‘atypical’ form may actually dominate CD manifestation and
consequently ‘non-classic’ as a division title has come into recent favor (Nejad et al 2009). Rampertab et
al (2006) describe a shift toward diagnosis of non-classic phenotypes since the 1950s: prior to the 1980s
the initial presenting symptom was diarrhea in over 90% of CD patients. After 2000, less than 40% of
persons diagnosed with CD initially present with diarrhea (Lo et al 2003). Rawal et al (2010) report
similar findings. It stands to be seen whether this change is attributable to changes in diagnostic
processes but Rampertab et al (2006) suggest that sociocultural trends such as breastfeeding practices
may be a factor. Lastly, there is evidence to suggest that periods of gluten intake and withdrawal over
time may change the phenotype of CD within the same individual (Kurppa et al 2008).
Below is a basic outline of known CD symptoms (Table 11):

Classic Symptoms
Abdominal pain
Anemia*
Anorexia
Constipation*
Diarrhea
Foul-smelling stool
Fatigue
Vomiting*
Weight loss
Short stature
Irritability

Non-Classic Symptoms
Alopecia
Arthritis
Dermatitis herpetiformis
Delayed Puberty*
Depression
Dyspepsia
Hepatitis
Infertility
Multiple miscarriages
(women)
Migraines
Obesity
Iron deficiency

Table 11. Division of some CD symptomology in to classic and non-classic categories (as listed by
Nejad et al 2009 and Torres et al 2007). *Classification of symptom differs between sources.
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The difference between classic and non-classic CD (as listed here) is the presence/absence of
gastrointestinal symptoms (Nejad et al 2008; Torres et al 2007) (Table 11). Sources disagree on the
exact symptom division of these two groups. Furthermore, patients with classic CD commonly exhibit
non-classic symptoms (Torres et al 2007) and many have only these non-classic symptoms. Confusingly,
persons without classic symptoms have been referred to as ‘asymptomatic’ or ‘silent’ (Ferguson 1993;
Tack 2010) despite the clear presence of clinical manifestation. Instead, it appears that a spectrum of
phenotypes exist (Tack et al 2010) and CD may be better illustrated by symptom grouping based on
affected organ/tissue (as in Dickey 2009), with recognition that individual manifestations are diverse,
likely from variability in pathogenesis (Table 12). Gastrointestinal issues can be sub-grouped into those
pertaining to malabsorption and dysmotility (Tursi 2004).
GASTROINTESTINAL SYMPTOMS
Malabsorption Issues
Diarrhea, steatorrhea
abdominal cramps, bloating
Weight loss
Dysmotility Issues
Vomiting
Epigastric pain
Constipation
Heartburn
NON-GASTROINTESTINAL SYMPTOMS
Hematological Symptoms
Iron, B12 and/or folic acid deficiency
Anemia
Hyposplenism
Liver-related Symptoms
Abnormal liver chemistry
Skin/Mucous Membrane Symptoms
Dermatitis herpetiformis
Alopecia areata
Aphthous mouth ulcers
Rheumatological Symptoms
Arthritis
Bone-related Symptoms
Osteoporosis
Osteomalacia

Paul et al 2010
Harper et al 2007
Bullen et al 1980
Rubio-Tapia and Murray 2007
Marietta et al 2007
Neuhausen et al 2008
Malahias et al 2009
Zhernakova et al 2011
Bianchi et al 2008
Jafri et al 2008
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Tooth enamel defects
Malahias et al 2009
Hypocalcaemia
McNicholas and Bell 2009
Increased fracture risk
Bianchi et al 2008
Gynecological Symptoms
Late puberty/late menarche
Bona et al 2002
Infertility
Freeman 2010b
Recurrent miscarriages
Anjum et al 2009
Neurological Symptoms
Cerebellar ataxia
Burk et al 2001; Hadjivassiliou et al 2003, 2006
Partial seizures/epilepsy
Freeman 2008; Hadjivassiliou et al 2010
Migraines
Zelnik et al 2004
Peripheral neuropathy
Alaedini et al 2002
Other/Mixed
Chronic Fatigue
Jorda and Vivancos 2010
Anxiety and/or depression
Collin et al 2008; Hauser et al 2010
Short Stature
Troncone and Kosova 2010
Colon polyps
Casella et al 2010
Selective IgA deficiency
Collin et al 1994
Table 12: Known CD symptomology sorted by affected tissue/organ system and relevant
citations. Suggested readings are provided for ‘non-classic’ symptoms.
Hematological Symptoms
Iron, B12 and folic acid are common deficiencies in CD and many persons are anemic at time of
diagnosis (see Halfdanarson et al 2007). Other hematological associations have been noted:
thrombocytosis, thrombocytopenia, leukopenia, venous thromboembolism, and hyposplenism (Bullen
et al 1980). Anemia has generally been considered an effect of malabsorption in CD but recent work by
Harper et al (2007) suggests that this is not the case and that inflammation must also be involved.
Current hypotheses include absorptive issues of iron, increased blood loss in feces, and anemia of
chronic disease (mediated by pro-inflammatory cytokines) (Hersko and Patz 2008). Hershko and Patz
(2008) summarize the current findings of CD and anemia: As many as 50% of persons detected by
various population screenings have been found to be anemic. Approximately 5% of persons who exhibit
iron deficiency anemia have been found to have CD.
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Liver-related Symptoms
Rubio-Tapia and Murray (2007) conducted a review of current research discussing liver-related
symptomology of CD. Hypertransaminasemia is present in approximately 40% of adults and 54% of
children with CD upon diagnosis. CD associated with a 2-6x risk for liver disease. The underlying
physiology of this connection is unknown. Autoantigens for tTG have been reported in the liver and it is
proposed that there is a proximal activation of the inflammatory response that results in damage to the
liver.

Skin-related Symptoms
Dermatitis herpetiformis (DH) is considered the cutaneous manifestation of CD that occurs in 4.5-33% of
CD (Collin and Reunala 2003; Collin et al 1994; Marietta et al 2008). Epidermal transglutaminase (TGe) is
closely related to tTG, both of which are considered autoantigens in DH (Marietta et al 2008). The
reasons for this connection remain unclear (Marietta et al 2008). Several other skin conditions
associated with CD appear more commonly in those who also display DH: oral mucosal lesions, alopecia
areata (Neuhausen et al 2008) and vitiligo. Aphthous mouth ulcers are significantly associated with CD
and Malahias et al (2010) have suggested clinicians to examine the mouth when diagnosing CD.

Bone-related Symptoms
Several bone-related conditions are associated with celiac disease: low bone mineral density (BMD),
hypocalcaemia, osteopenia, osteoporosis, and osteomalacia (see Bianchi et al 2008 for review). The
connection likely lies in the metabolic alterations present in CD that in turn affect bone and mineral
metabolism. The two most tenable hypotheses involve the increased release of pro-inflammatory
cytokines in CD as a result of chronic inflammation and nutrient malabsorption (such as calcium). Low
BMD can be directly linked to malabsorption issues and osteoporosis (and osteomalacia) is purported to
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come from a decrease in calcium uptake (or possibly vitamin D deficiency) that leads to the
development of an overactive parathyroid (hyperparathyroidism). However, hyperparathyroidism
appears to be rare in CD and limited to case reports (Collin et al 2002). Additionally, leptin plays a role in
bone remodeling and correlates with BMD (Hamrick and Ferrari 2008). Leptin levels are reduced in
children with CD (Ertikin et al 2006). Jafri et al (2008) have suggested that earlier detection of CD will
help reduce the risk of fractures form bone related changes. Dental enamel defects (linear enamel
hypoplasia) have been significantly correlated with CD and can be physiologically attributed to early
onset CD (prior to or during enamel formation) (Malahias et al 2010). Rashid et al (2011) reviews the
oral manifestations of CD and encourages dentists to help play a role in CD diagnosis, as enamel defects
and mouth ulcers may be the only outward manifestations of CD in some individuals.

Gynecological Symptoms
Some women with undiagnosed CD experience frequent miscarriages (Sheiner et al 2006). Tissue
transglutaminase is widely expressed in placental tissue (Robinson et al 2007), the function of is not fully
elucidated. Anjum et al (2009) report the appearance of IgA-tTG in tissue staining along the outermost
maternal-facing layer of the placenta (syncytiotrophoblast plasma membrane) that may reduce
placental function. Approximately 4-8% of women with unexplained infertility have been subsequently
diagnosed with CD (Meloni et al 1999). Freeman (2010b) has suggested that CD might be provoked by
exposure to fetal antigens during pregnancy.

Neurological Symptoms
Approximately 10% of persons with CD also suffer from a neurological disease- especially peripheral
neuropathy and cerebellar ataxia (Burk et al 2001; Willis and Hovell 1996). Opthalmoplegia, epilepsy,
encephalopathy, myopathy, Stiff-man syndrome, neuromyotonia, myelopathy, and dementia have also
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been observed (Hadjivassiliou et al 2010). Anti-ganglioside antibodies present in patients with celiac
disease correlated with the presence of peripheral neuropathy (Alaedini et al 2002). CD patients
screened for serum anti-ganglioside displayed distal sensory loss. Alaedini et al (2007) suggest that
some neurological disorders associated with CD may be due a cross-reactivity of anti-gliadin antibodies
to neuronal synapsin I. However, anti-synapsin antibodies are observed in CD cases with and without
neurological symptoms.
Gluten-related ataxia is the most common cause for sporadic idiopathic ataxia, based on antigliadin antibody testing (20% of all ataxia) (Pellecchia et al 1999; Hadjivassiliou et al 2003). A sample of
224 ataxia patients in the UK have shown that only 13% presented with gastrointestinal symptoms but
over 70% were positive for the HLA-DQ2 risk allele. A more recent study by Hadjivassiliou et al (2006)
observed widespread deposition of IgA-tTG in the cerebellum, pons and medulla of patients with gluten
ataxia that was absent in non-gluten ataxia. Freeman (2008) reviews the possibility that some
neurological symptoms may be the result of vitamin deficiencies: Vitamins B1, B6, B12, E, and niacin
deficiencies are all known to be associated with neuropathy. B1, B12 and niacin are known to be
associated with cerebellar ataxia.
Depression and anxiety are common in CD (Collin et al 2008). There is evidence that anxiety
does not completely resolve with gluten free diet (Hauser et al 2010).

Other Symptoms
Casella et al (2010) analyzed a group of adults with CD over the age of 40 on gluten free diets (n=42) for
abnormal colonoscopic findings. Polyps, diverticula, and inflammatory changes presented in 26% of
patients. Lymphocytic colitis, malanosis coli, rectal histiocytosis were found in 36% of participants. The
control group exhibited none of these symptoms. Additionally, persons with CD showed an elevated
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presence of eosinophils compared with controls. It is suggested that colonoscopies be performed in
subjects suspected of CD.

Comorbid Conditions
A host of additional conditions have appeared in conjunction with CD (Table 14). Note that the
distinction between comorbidity and clinical symptomology of CD is difficult because there is still
insufficient research to explain extra-intestinal manifestations, as demonstrated by the continued
disagreement between classic and non-classic symptoms (Alaedini and Green 2005). Given the multisystemic nature of CD, it is possible that some of these ‘comorbid’ conditions may be instead
etiologically related. The following conditions have been described as comorbid with CD:

CONDITION
Addison’s Disease*
Autoimmune Gastritis*
Autoimmune Hepatitis*
Autoimmune Thyroid Disease*
Autism
Behçet Disease*
Dermatomyositis*
Eczema*
Fibromyalgia
Irritable Bowel Syndrome* (Crohns
Disease)
Lactose Intolerance
Lupus Erythematosus*
Multiple Sclerosis*
Myasthenia Gravis*
Non Hodgkins Lymphoma
Peptic Disease
Primary Biliary Cirrhosis*
Primary Sclerosing Cholangitis*
Psoriasis*
Schizophrenia
Sjögren Disease*
Small Intestinal Cancer

Suggested Reading
O’Leary et al 2002
Stancu et al 2001
Tovoli et al 2010
Elfstrom et al 2008
Vojdani et al 2004
Zamani et al 2009
Song et al 2006
Collin and Reunala 2003
Zipser et al 2003
Casella et al 2010
Ojetti et al 2005
Mirza et al 2007
Rodrigo et al 2011
Tack et al 2010
Goldacre et al 2008
Levine et al 2009
Rubio-Tapia et al 2007
Hay et al 1988
Collin and Reunala 2003
Cascella et al 2009
Collin et al 1994
Elfstrom et al 2011
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Type 1 Diabetes Mellitus*
Vitiligo*

Frisk et al 2008
Tack et al 2010

Table 13. Conditions that have been described as comorbid with celiac disease. Asterisks (*) are
placed next to autoimmune conditions. Note: This list is not exhaustive, but represents some of
the commonly cited findings for comorbidity.
Autoimmune Conditions
Many conditions comorbid with CD are autoimmune disorders (Somers et al 2006; Somers et al 2009).
Many autoimmune conditions not listed here have been reported in conjunction with CD. This is
entirely consistent with the observation that multiple autoimmune conditions tend to appear both
within individuals and families (Cooper et al 2009). As much as 25.6% of participants with CD display
one or more additional autoimmune disorders (Bardella et al 2009, n=297). Part of the explanation may
be that HLA-DQ2 and -DQ8 risk alleles are associated with numerous autoimmune conditions (Kumar et
al 2001).
Autoimmune thyroid conditions and type I diabetes are some of the most commonly comorbid
conditions for CD. CD, autoimmune thyroid disorders, and AIDDM all share the HLA-DQ2 risk allele
(Kumar et al 2001). CD occurs in approximately 4.1% of diagnosed autoimmune insulin-dependent
diabetes mellitus (AIDDM) (Collin et al 2007). This number is based on a prevalence synthesis of 40
screening surveys conducted between 1987 and 2001 (n=16194 adults and children). Persons with both
CD and AIDDM tend to mild to no gastrointestinal symptoms. Some have suggested the two conditions
to be resultant of each other, a claim that is supported by mutual increased risk of subsequent
development for the second condition (Kumar et al 20010. CD and AIDDM have other shared risk alleles
apart from HLA-DQ: RGS1, IL18RAP, and TAGAP (Smyth et al 2008). Thyroid disorders are found in
approximately 5% of person with CD (Collin et al 2007). Elfstrom et al (2008) found significant
association between CD and subsequent hypothyroidism (Hashimoto’s Thyroiditis), thyroiditis and
hyperthyroidism (Grave’s Disease) (hazard ratio= 4.4, 3.6, 2.9, respectively) and that these risk values
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were increased slightly in children (p<0.001). Thyroid disease and subsequent CD is also observed for all
three of these thyroid conditions (p<0.001).
Other autoimmune disorders have similar comorbidity rates: Sjogren’s Syndrome is found in
3.3% of CD compared with 0.3% in health controls (Collin et al 1994) (p=0.0059). A screen for CD within
a group of patients with Addison’s disease (AD) found a prevalence of 12.2% (n=46) (O’Leary et al 2002).
Dermatomyositis has been reported in co-occurrence with CD only three times in the literature up
through 2006 (Song et al 2006). It is reported to respond positively to a gluten free diet. Similarly,
autoimmune gastritis is very rare but has been reported in conjunction with CD and noted to improve
with gluten-free diet (Stancu et al 2001).

Diagnosis
Diagnostic procedures for CD may include histological examination, serological testing, genetic testing,
treatment with gluten free diet, as well as basic symptom observation (Dickey 2009). Typically diagnosis
is based off positive serology and histology. Clinicians commonly choose to conduct serological tests
prior to scheduling a duodenal biopsy (Kelly 2004) unless there is a high clinical suspicion of CD (Green
2009).
Serological (blood) testing is one of the least invasive and affordable procedures used in CD
diagnosis. For adults, the best serological tests look for antibodies to tTG and deamidated gluten
peptides (DGP) (Hill 2004). Anti-gliadin (AGA) and anti-endomysium (EMA) appear to be better for
children under the age of 2. Tests for IgG antibodies are commonly used in situations where a patient
has selective IgA deficiency (Prince et al 2000; Vermeersh et al 2010). Note: Persons with selective IgA
deficiency are 10x more likely to develop CD (Collin et al 1994). Two of the important factors of testing
are the sensitivity and specificity values for the test, which are the percentages of true positives and
true negatives, respectively (Table 14). Sensitivity and specificity values are also known to fluctuate
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based on age, CD phenotype and degree of histological damage: Abrams et al (2006) analyzed the
sensitivity and specificity for various anti-tTG antibody tests used by two popular commercial labs and
found significant variability in these values. Sensitivity in particular is lower for patients with only partial
villous atrophy compared with those demonstrating total villous atrophy (42.3% versus 90.0%,
p<0.0001). (Freeman 2004; Hopper et al 2007). Anti-gliadin testing has been largely abandoned due to
low sensitivity (Armstrong et al 2011). No serological test for CD is perfect (100%) for either of these
parameters and they are generally used in combination with other diagnostic methods.

Test Sensitivity
Specificity
Accuracy
IgA-tTG
78%
98%
90%
IgA DGP
74%
95%
86%
IgG DGP
65%
98%
84%
IgG + IgA DGP
75%
94%
86%
IgA AGA
63%
90%
79%
IgG AGA
78%
98%
90%
Table 14. Sensitivity and specificity values of various serological tests for CD in adults (values
from Rashtak et al 2008).
Histological exam has long been considered a “gold standard” in CD diagnosis (Dickey 2009; Freeman et
al 2011). In this procedure, a small biopsy is taken from the duodenum and examined for evidence of
villous atrophy and crypt hyperplasia as well as IEL lymphocytosis (an influx of IELs to the region).
Results are most often scored based on the Marsh-Oberhuber Classification (Marsh 1992; Oberhuber et
al 1999): (0) “Latent CD”- Abnormal serology tests but no IEL lymphocytosis or villous atrophy present;
(1) “Lymphocytic enteritis”- Normal villi with some IEL lymphocytosis; (2) IEL lymphocytosis plus some
villus atrophy; (3) Partial, near total or complete villous atrophy. Histological exams must be carefully
interpreted: Biopsy analysis is somewhat subjective and is known to vary between pathologists (Corazza
et al 2007). Gastric lymphocytosis criterion for CD is approximately 25 IELS/ 100 epithelial cells
(Carmack et al 2009). Villous atrophy and crypt hyperplasia are known to occur in other disease states
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including tropical sprue, giardiasis, autoimmune enteropathy as well as HIV enteropathy (Green and
Jabri 2006). Lastly, degree of intestinal damage does not correlate well with severity of symptoms (Brar
et al 2007; Murray et al 2008). Some researchers have described an over-reliance on histological testing
in clinical settings: Mohamed et al (2008) re-analyzed 14 patients who had failed diagnosis for CD,
based on the Marsh-Oberhuber classification, by using a test for antibodies (CD2, CD3, CD 7, CD8, CD69,
and Ki67) indicative of mucosal damage. Nine of these patients qualified for CD diagnosis.
Measurement of TCR-γδ+ cell levels has been recently shown to be a better detector of latent CD than
the Marsh I classification (Kaukinen et al 2007).
Genetic testing for the HLA-DQ2 and –DQ8 risk alleles are becoming more common use, as the
cost of genetic testing decreases (Green and Jones 2010). Note that these tests can only report on a
genetic predisposition that is required for CD development- not if the person has manifested CD.

Diagnostic Models
Phenotype labels for CD have been generated to fit current diagnostic procedures and the expanding
spectrum of diagnosed CD (Troncone et al 2004): “Latent/potential” CD indicates positive serology only.
“Asymptomatic/silent” persons have a positive serology and histology for CD but lack classic
symptomology. “Symptomatic” express all three conditions. Despite these labels, researchers and
clinicians have had some difficulty in generating a cohesive model for diagnosis; many diagnostic
procedures, even if used in conjunction, fail to catch the full clinical spectrum of CD. A 2009 study by
Tursi et al recruited 549 patients with CD for retrospective assessment. Less than half (47.7%) qualified
for classic/symptomatic description. Subclinical CD was in the slight majority with 47.7% and 6.6% fell
under the silent classification.
Ferguson et al (1993) was the potentially the first to suggest that a secondary factor is required
to exacerbate underlying genetic predisposition into disease development; Weinstein et al 1974 was the
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first to suggest the existence of a ‘proceliac’ state. Latent celiac disease has also been referred to as
subclinical, silent, occult celiac disease, low-grade enteropathy, potential celiac disease, gluten
sensitivity with mild enteropathy (summarized in Ensari 2010).
One of the largest pitfalls of current diagnostic procedure is the observation that the causes of
small intestinal destruction appear to be independent of the development of autoantibodies (Abadie et
al 2011) (see Pathogenesis). In attempt to ameliorate continued missed diagnoses, Catassi and Fasano
(2010) have supplied a simple “4 out of 5” model to be used in CD diagnosis (Table 15). As long as four
of the five criteria is met, the patient should qualify for CD diagnosis. If genetic testing is not performed,
the criteria should be followed as 3 out of 4.

1.
2.
3.
4.
5.

Presence of “Classic” Symptoms
Positive autoantibody IgA test.
HLA-DQ2 or –DQ8 genotype
Presence of enteropathy upon histological examination
Positive response to gluten free diet

Table 15. “Four out of Five CD Diagnosis Model”
Positive response to a gluten free diet cannot be taken as a proof-positive for CD: Campanella et al
(2008) believe that positive response to a gluten free diet should not be primarily used in CD diagnosis
because abdominal symptoms post-cereal ingestion are not entirely limited to CD (Kaukinen et al 2000).
They re-analyzed approximately 180 patients put on gluten free diets due to CD diagnosis and found
that only 51 qualified for diagnosis on the basis of histology and serological markers.
Treatment of CD is still limited to a strict gluten-free diet (Schuppan et al 2009), although many
researchers have attempted various therapeutic strategies (see Lerner 2009 and Sollid and Lundin 2009
for reviews).
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Complications of Celiac Disease
Approximately 2-5% of CD patients are considered refractory and will not recover when put on a gluten
free diet (Tack et al 2010). Refractory CD can be subdivided in to Types I and II based on cytometric
analysis of IELs (Daum et al 2005). Type I is characterized by a normal T-cell population and responds
well to steroid treatment. Type II refractory CD T-cells are abnormal, changes of which appear to be
associated with a TCR gene rearrangement and recurrent trisomy for chromosome 1q (a section of the
first chromosome appears in triplicate instead of duplicate). Prognosis of type II RCD condition is poor
because there is a greatly increased risk for development of malignancies. The 5 year survival rate for
type I is 80-96%, but only 44-58% for type II (Biagi et al 2010). Type II refractory CD with enteropathyassociated T-cell lymphoma has a survival rate of only 8%.
Many studies have described an increased risk for non-Hodgkin lymphoma in untreated CD (3-6
fold risk) (see Elfstrom et al 2011). Two types of lymphoma are notably observed in refractory CD
patients: enteropathy-associated T-cell lymphoma (EATL) and enteropathy-type intestinal T-cell
lymphoma (EITCL) (Farstad and Lundin 2003). As many as half of all Type II refractory CD patients will
develop one of these lymphomas (Al-toma et al 2007). Factors that contribute to the development of
refractory sprue include poor gluten-free diet compliance and delayed diagnosis (Freeman 2009). Silano
et al (2007) found that patients diagnosed with CD at a later age were at higher risk for developing
neoplasms compared with those diagnosed at earlier ages (n=1968). They utilized the Italian Registry of
Complications of Coeliac Disease (est. 1982) to look for subsequent tumor development in persons
diagnosed with CD at various collaborating centers in Italy from 1982 to 2005. Standardized incidence
ratio for all cancer was 1.3 (95%CI: 1.0-1.7, P<0.001). SIRs for specific cancer forms were: non-Hodgkin
lymphoma 4.7 (95% CI: 2.9-7.3, p<0.01), small bowel adenocarcinoma 25 (95% CI: 8.5-51.4, p<0.001),
Hodgkin lymphoma 10 (95% CI: 2.7-25, p=0.01), and stomach carcinoma 3 (95% CI:1.3-4.9, p<0.08).
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Mean age for persons with CD who were diagnosed with cancer was higher than those who did not
develop cancer (47.6±10.2 years versus 28.3±18.2 years) (p<0.000).
Malignancies are not the only complications of CD: Tursi et al found 3.3% of CD patients on
gluten-free diets developed complications that also included secondary autoimmune disease,
myocardial infarction, and recurrent miscarriages.
Vitamin B deficiencies are of notable concern for those on a gluten-free diet (Thompson et al
2005). Hallert et al (2009) conducted a double-blind placebo-controlled study of B-vitamin
supplementation in CD patients for 6 months (n=65). Participants were assigned to 2 groups: one
receiving daily doses of folic acid (B9) (0.8 mg), cyanocobalamin (B12) (0.5 mg), pyridoxine (B6) (3mg) and
the other a placebo. Vitamin-B and homocysteine levels as well as psychological well-being were
measured post-experiment and it was found that persons receiving vitamin supplementation had
significantly improved well-being (p<0.01) with reduced anxiety and depression (p<0.05 each).

NON-CELIAC GLUTEN SENSITIVITY
In March 2011, Sapone and colleagues published the first article to confirm “Gluten Sensitivity” (NCGS)
as a condition separate from CD: Gluten-sensitive, celiac, and control groups were enrolled in a gluten
challenge under clinical supervision for four months (n=26, 42, and 39 respectively). Post challenge they
underwent serological, genetic and histological analyses for markers of CD. Post analysis they were put
on a gluten-free diet and monitored for improvements. Here, gluten sensitive individuals are those who
fail to display positive serology for autoantigens and do not have histological damage yet still do poorly
on gluten-containing diet. Many symptoms overlap CD and GS, although GS symptomology appears to
be less severe.
Sapone et al (2011) found that GS symptoms improved more quickly on GFD (days). Half of
NCGS patients (48% were positive for anti-gliadin antibodies (AGA) and over half displayed the HLA-DQ2
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or –DQ8 markers. AGA presence and HLA markers did not correlate. Persons with CD had significantly
increased intestinal permeability relative to NCGS patients (p=0.0138). NCGS patients actually had
better barrier function (per lactulose/mannitol urinary ratio) than healthy controls (p=0.0308).
Expression of tight junction protein claudin 4 (CLDN4) was found to be higher in NCGS relative to either
CD or healthy controls (p=0.0286). (CLDN4 is thought to decrease tight junction permeability).
Autoimmune antibodies were not found in the NCGS patients or controls. Bowel biopsy for NCGS
showed at most minor affect. NCGS patients displayed higher levels of IELS relative to normal ranges
(still lower than those in CD). Cytokine IL-6 levels were significantly elevated in CD but not in NCGS.
NCGS patients also showed a reduced expression of IFN-γ.
Changes in IELs and the presence of AGA suggest the involvement of the adaptive immune
system, although to a lesser degree as compared with CD. Given the increase in IL-6, NCGS may be an
inflammatory response generated primarily through innate immune system pathways. The results of
this study largely confirm the hypotheses from prior work from the same group (Sapone et al 2009).
However, further research is needed to better characterize the etiology of this condition.

67
METHODS

PROJECT GOALS:
Previous research indicates that persons affected by CD in US often feel that diagnosis was too delayed
(Green et al 2001) (n=1612, most diagnosed at ages 40-50). Current data shows that average delay for
CD diagnosis in the United States is approximately 11 years (Fasano et al 2003). Such delays may reflect
the lack of information and relatively low importance of food allergies from general practitioners and
some internists (Gupta et al. 2008, 2009, 2010).
The goal of this research is to characterize the diagnostic trajectories for gluten-averse
conditions and make suggestions for decreasing time to diagnosis.

SURVEY DESIGN
A questionnaire was generated, modeled partly after Cranney et al (2003) and Green et al (2001)
(Appendix I: Gluten-Averse Condition Survey). The local Bellingham Gluten Intolerance Group (BGIG)
assisted in the construction. A subset of the questionnaire was used for this project:
•

Background Information: age, sex, height, weight, education, marital status, occupation, and
income.

•

Personal Path to Diagnosis: breastfeeding, travel outside the US and Canada, frequency of food
related illness in the US, initiation of diagnostic process, medical professionals consulted,
timeline of diagnosis, testing performed, final diagnosis, and if first in family to be diagnosed.

•

Symptom Inventory: on Lickert scale for before diagnosis and after diet change.

•

Additional Presenting Diseases/Conditions: for participant and family (mother, father, brother,
sister, grandparents, children and grandchildren.

68
PARTICIPANT SAMPLING
Participants recruited through BGIG and also using an on-line solicitation (Survey Monkey) and snowball
sampling. Both affected individuals and “friends” of affected individuals that are the same sex and close
to the same age (controls) filled out the same questionnaire (copies attached). Here, only the results of
the affected individuals were used.

STATISTICAL ANALYSES
All statistical analyses were performed using SPSS 19.

ETHICS
The questionnaire and sample design were approved for an exemption by the Human Subjects Review
Committee at Western Washington University.
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RESULTS

CHARACTERIZATION OF SAMPLE
A total of 35 individuals responded to the survey (n=35).

Age
Range of 21-89 years, mean = 57.02 +/- 14.42 years, median = 59 years.

Sex
Females made up the majority of the sample (n=32); only 3 males in the sample.

Menopause Status
Of the women in the study, 21.9% were premenopausal (n=7), 15.6% were perimenopausal (n=5), and 62.5% were post-menopausal (n=20).

Ancestral origins
All participants who responded to this section were of mixed European ancestry (n=33). Two
individuals did not respond on this question.

Family income
Family income sections were answered by 31 participants. Twenty reported incomes over 50K
(57.1%), 8 reported incomes over 100k (25.8%).

Marital Status
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All responded to marital status: 74.3% were married (n=26), 5.8% were widowed/widowers
(n=2), 14.3% were single (n=5), and 5.8% were cohabiting with mate (n=2).

Years of Education
All participants responded to the education questions: All but 1 indicated that they had
attended at least some college classes. Approximately 28.6% indicated education through
graduate school (n=10). Twenty-five participants reported on their particular training: 28% of
those had bachelor’s degrees in the hard sciences (biology or math/computers) (n=7), 33.3%
had bachelor’s degrees in the social sciences (n=12), and 16.7% had humanities degrees (n=6).

PATH TO DIAGNOSIS
All quotes are provided with anonymous participant number (e.g. P29).

Age at Diagnosis
All participants provided approximate age at diagnosis. Average age at diagnosis was 49.7+/13.2 years (median=53), range of 19-77 years. Age at diagnosis for persons who identified as
‘gluten intolerant’ was 50±13.8 years (median = 48). For persons with CD, average age at
diagnosis was 51.8 ±12.2 years (median = 55).

Initiation of diagnosis (Who)
Open ended question: “Can you supply any other details about the context that started the
diagnostic process?”
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Over half of the participants stated that they initiated their diagnostic process (58.3%). Medical
professionals initiated diagnosis in 27.8% of cases.

“Gynecologist concerned about osteopenia- referred to [general practitioner]. GP found
Celiac with blood test and also low vitamin D.” (P29)
“It was noted that I was extremely anemic in 2005.” (P66)

The remainder of diagnoses began with encouragement from friends/family (some whom were
also diagnosed):
“My weight dropped to 98 lbs and my mom demanded that I be seen by a gastrospecialist.” (P8)
“A friend strongly urged me to go to her naturopath to be check for gluten intolerance.”
(P14)
“I self-diagnosed because my sister was diagnosed about 20 years before me and I
began having classic symptoms (diarrhea).” (P16)
“Had bad stomach pain- consulted sister who is gluten intolerant. Self-diagnosed by
diet elimination.” (P139A)
“Friend heard of Celiac on NPR and suggested I get tested” (P150A)
Initiation of Diagnosis (Why)
Open-ended question: “Can you supply any other details about the context that started the
diagnostic process?”

Approximately one-third of participants stated that the diagnostic process was started due to
gastrointestinal problems (31.4%). Answers to this section were highly varied and also included:
unexpected finds of colonoscopy (n=2), dermatitis herpetiformis (1), heartburn (1), osteopenia
(1), joint pain (1), relative/friend diagnosed with ‘gluten intolerance’ (2), family member
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diagnosed with Lupus Erythematosus (1), lack of positive response to years of psychiatric
treatment (1), anemia (3), weight loss (2), migraines (2), constant sinus infections (1), and
recurrent bouts of yeast infection (1).
“I always had GI problems in high school, (doctors) told me it was IBS, got really sickparasite in Mexico and came back and [doctors] tested me for Celiac- positive.” (P1)
“Suspected sensitivity to wheat based on systemic inflammation.” (P16A)
“Dermatologists discovered I had dermatitis herpetiformis.” (P24)
“Tried to determine what caused my heartburn.” (P26)
“I ended up in hospital.” (P34)
“Routine colonoscopy because of family history of colon cancer.” (P40)
“I went in because I just never felt good, always tired, muscles hurt, headaches almost
every day.” (P59)
“Persistent rash. Consulted naturopath (once insurance finally covered). She diagnosed
very low adrenal function and treated. Further testing showed hypothyroidism and
then gluten intolerance. I ignored the [diagnosis] until eating several pieces of bread
one morning resulted in joint inflammation (severe) within 30 minutes.” (P58)
“I was sick all the time, had bad skin, brittle hair and racked bleeding hands so I tried
going to a naturopath.” (P49A)
Interactions with Medical Professionals
Open ended question: How many and what kinds of medical professionals did you consult?
Please provide rough dates (or timing) for the steps in the process):

Number of medical professionals consulted
Participants most often saw 2 professionals leading up to diagnosis (mode = 2, n=12). Two
participants did not consult professionals and were entirely self-diagnosed. It was not
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uncommon for individuals to see multiple professionals along their path to diagnosis: 3
professionals (n=6), 4 (n=4), 5 (n=2). One saw 10 different professionals in pursuit of diagnosis.

“GP- 1984, OB/GYN- 1995; gastroenterologist- 1996; endocrinologist 1996; naturopath
1998; GP (new) 2000, 2002; physical therapist 2006; allergist 2001, 2002, 2005)”
(P112A)
Experiences with Medical Professionals
Some participants described negative experiences with various medical professionals and/or the
diagnostic process:
“Sister has celiac and lupus- changed doctor because she refused to test me when I
asked.” (P46, who later tested positive for ‘classic’ CD)
“Chronic constipation- 30 years ago I was told to ‘loosen up’ because ‘you have a spastic
colon’ by a very creepy doc. I didn’t talk about this again until recently.” (P66)
“Dr. didn’t agree to do (blood test) for Celiac. Do not think the Dr. was knowledgeable
on gluten and those issues.” (P143A)
Some participants noted positive experiences with medical professionals:
“Under care of psychiatrists in 1987: Second doctor (neurologists and psychiatrist) after
6 years of management suggested investigating food because I responded well to antiseizure medication. [The nutritionist] suggested trying ketogenic diet and/or modified
Atkins- but had to get guidance from internist; Good nutritionist.” (P59)
Testing
Six participants had genetic testing done, of which 5 indicated ‘positive’ results.

Blood testing was done for 22 individuals- 20 of which indicated ‘positive’ results. Three
participants described their results as “off the chart” (P17, P19, P150A). Two individuals listed
anemia under their blood test results (P48, P66).
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Twenty individuals had endoscopies, of which 14 reported ‘positive’ results. Three participants
were on a gluten free diet when endoscopies were done and had negative results (P17, P59,
P61). Three participants mentioned the findings of precancerous polyps (P48, P61, P112A). P8
described their endoscopy results as “raging celiac”.

Ten participants state additional testing including colonoscopies (P7, P34), MRI (P34), ultrasound
(P34), CAT scan (P34), stool samples (P36, P61) and urinalysis (P34).

Diagnosis
Three participants indicated they were “gluten sensitive”, 9 described themselves as “gluten
intolerant”, 20 were diagnosed with “Celiac Disease” and 2 had “gluten allergy”.

Possible Diagnostic Confusion
Some checked multiple boxes for their diagnosis even through their listed test results indicated
that they were CD- some of those who indicated that they were Celiac also indicated gluten
intolerance (P36, P46, P48, P61). One participant indicated that she was diagnosed with ‘wheat
allergy’ even though she reported daily long-term adverse reactions to food (P52). One
participant stated that they were gluten intolerant and ‘probably’ Celiac because of their
dermatitis herpetiformis (P61). One participant did not know their particular diagnosis at all:
“Not clear during consultation- Dr. said stop eating gluten.” (P7)
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Family Diagnoses
Most participants were the first in their family to be diagnosed (n=27, 77.1%). Family members
diagnosed first included sisters (n=4), brothers (n=2), granddaughter (n=1), and a female cousin
(n=1). Some participants left additional comments about affected family members.

“[My mother] died at 47 years of age, adrenal disorder, and highly suspect Celiac. [My
father] died at 68 years old of Parkinson’s. As I look back, I think he had Celiac too. My
[siblings] will not be tested due to lack of reliable testing. They use elimination diets to
identify foods that are causing illness. My eldest brother is very sick, with many
diagnoses, which prevents him from tolerating the rigors of an elimination diet, and
lacks health care.” (P67)
“My 3 yr old grand-daughter who is now 12 [was the first to be diagnosed]. Since that
diagnosis we have 6 in the family, 4 generations ages 8-87 and probably more.” (P17)
Time to Diagnosis
Twenty-three participants provided a timeline to diagnosis. Months to diagnosis varied greatly
(median= 26 months, IQR= 3 -228 months, range 0-53 years). The most extreme delayed
diagnoses were: 48 years to CD diagnosis (P71), 33 years to CD diagnosis (P67), and 28 years to
‘gluten intolerant’ (P68).

“1990, gastroenterology, upper endoscopy for heart burn. Found possible Celiac but
wasn’t sure- said I didn’t have usual symptoms- diarrhea, etc.” (P26) (20 years to
diagnosis, Celiac Disease).
“Decades (early 1970s) of GI symptoms, various doctors, finally one that looked at
celiac- 2006” (P36) (31 years to diagnosis, Celiac Disease).
“I was having constant diarrhea, losing weight, severe stomach pains…Numerous trips to
doctors from childhood on for stomach problems” (P71) (48 years to diagnosis, Celiac
Disease).
“My brother and I have been ill since childhood. Overtime symptom list expanded and
symptoms worsened. Since 1978-2011: primary doctor, psychiatrist, women’s doctor
and surgeons, allergist, gastroenterologist (he said my stomach problems were
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emotional stress), naturopaths, eye doctor, dermatologist, cardiologist, neurologist.”
(P67) (33 years to diagnosis, Celiac Disease).
Participant P68 was never formally diagnosed by medical professionals due to ‘negative’
blood testing. “[No diagnosis], but my doc suggested I try being gluten free for 3
months- which I did.” This patient self-diagnosed as ‘gluten intolerant’.
Average time to diagnosis for persons with “gluten intolerance” (211 ±116.83 months, n=5) was
significantly longer than those who were diagnosed with CD (88.9 ±122.0 months, n=14)
(Welch’s t=1.98, df=10.8, p<0.05 single tailed). Given that both groups had extreme outliers,
median values were also calculated: 240 months for ‘gluten intolerant’ and 36 months for CD.

SYMPTOMOLOGY
Proportions of persons reporting “none” (1) and “all of the time” for symptoms before diagnosis and
after diet change are presented in Table 16.

Commonality
The most common symptoms reported prior to diagnosis related mostly to gastrointestinal
issues. The mode for all symptoms prior to diagnosis was “1” or “none of the time” with the
exception of abdominal distension (mode =3), abdominal pain (4), diarrhea (3), flatulence (3),
and moodiness (bimodal= 1, 2). For these conditions 8.8%, 20%, 11.4% and 45.8% of
participants were unaffected by these conditions prior to diagnosis (respectively). The most
common symptom based on median was abdominal pain (median = “4” or “most of the time”).
Abdominal distension, flatulence, diarrhea, chronic fatigue, frequent sinus congestion, anemia
and moodiness all had a median of “3” or “some of the time”. Esophageal reflux, constipation,
brain fog, steatorrhea, bulky pale stool, frequent canker sores and failure to thrive had a median
of “2” or “a little of the time”.
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Epilepsy and multiple sclerosis were not reported as symptoms within the study. PCOS was
reported for 4 women. Two people reported symptoms of cerebellar ataxia prior to diagnosis.
Two women reported problems with recurrent miscarriage at or before diagnosis. One person
reported Crohn's Disease symptoms. Vitamin deficiencies were reported for 16 participants.
Chronic depression was reported for 17 individuals. Numbness/pain in hands/feet was reported
among 13 participants.

Some participants listed additional symptoms, although they did specify if there was change
post-diet change: “Atypical bipolar, mitochondrial dysfunction, dementia, slowed speech,
extreme chronic fatigue, short term memory loss, asthma, rosacea, and keratoconus” (P59);
“Low thyroid, Low vitamin D levels” (P14); “Hyperactive thyroid” (P17); “Ridged fingernails,
rosacea, facial acne” (P36); “Mucus in bowels” (P47).

Severity
Anemia and frequent sinus congestion were the most severe prior to diagnosis; 22.9% each of
participants reported that these were problems ‘all of the time’. Chronic fatigue, moodiness
and abdominal distension ranked “5” among 20% of participants, each. Chronic esophageal
reflux and diarrhea were reported “5” each for 17.1% of participants.

Symptoms Post-Gluten-Free Diet Change
Frequent sinus infections resolved entirely for 3 of 22 affected individuals and were otherwise
reduced in all but 2 people upon diet change. Moodiness resolved entirely for 8 of 26 affected
people, and was reduced in all but 2 persons. Esophageal reflux resolved for 1 person out of 19
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affected and was reduced in the rest except for 1 person. Vitamin deficiencies resolved for 6
out of 16 affected individuals and were otherwise reduced in all but 1 person. Chronic
depression resolved entirely for 5 of the 17 affected individuals and reduced in the remainder
except for one. Twelve persons reported presence of itchy skin rash even after diet change.
Numbness/pain in hands/feet resolved for 2 people and was otherwise reduced in all but one.
Osteoporosis, osteopenia, and osteoarthritis did not respond to dietary change, except for in
one individual. Symptoms of PCOS resolved entirely for 2 women, reduced for 1 and remained
the same for one. One of the women that reported resolve symptoms also stated that she had
surgery for the condition. After diet change only 1 still showed symptoms of cerebellar ataxia
(out of 2). Recurrent miscarriage resolved for one woman (of 2) upon diet change. Only one
person showed decreased symptoms for spinal cord problems (all of time to some of time).
Atherosclerosis was reported for only one individual, it did not reduce in severity upon diet
change. The person with Crohn’s Disease symptoms reported a disappearance of symptoms
after diet change. One person appears to have developed fatty liver disease after diet change.

For all symptoms considered, the percentage of persons reporting ‘none of the time’ increased
after diet change (p=1.18E-5). The percentage of persons reporting chronic symptoms also
decreased after diet change (p=3.33E-7).
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SYMPTOM Median
abdominal distension
3
abdominal pain
4
anorexia
1
brain fog
2
bulky, sticky, pale stool
2
diarrhea
3
flatulence
3
failure to thrive
2
muscle wasting
1
steatorrhea
2
vomiting
1
weight loss
1
hair loss
1.5
anemia
3
frequent canker sores
2
osteoarthritis
1
rheumatoid arthritis
1
cerebellar ataxia
1
chronic fatigue
3
constipation
2
Crohn's disease
1
dental enamel defects
1
itchy skin rash
1.5
epilepsy
1
esophageal reflux
2
fatty liver disease
1
frequent miscarriages
1
spinal cord problems
1
obesity
1
osteoporosis
1
osteopenia
1
Multiple Sclerosis
1
numbness/pain in
1
feet/hands
moodiness
3
chronic depression
1.5
Polycystic ovary Syndrome
1
frequent sinus congestion
3
high blood pressure
1
atherosclerosis
1

BEFORE DIAGNOSIS
None
Always
No
(1)
(5)
Answer
17.1%
20.0%
2.9%
8.8%
11.4%
2.9%
68.6%
2.9%
11.4%
40.0%
8.6%
2.9%
42.9%
2.9%
8.6%
20.0%
17.1%
2.9%
11.4%
14.3%
2.9%
57.1%
14.3%
2.9%
57.1%
8.6%
5.7%
42.9%
8.6%
5.7%
85.7%
0.0%
2.9%
71.4%
8.6%
5.7%
48.6%
2.9%
2.9%
40.0%
22.9%
2.9%
45.7%
2.9%
2.9%
65.7%
2.9%
2.9%
85.7%
0.0%
5.7%
82.9%
0.0%
11.4%
31.4%
20.0%
5.7%
37.1%
14.3%
2.9%
94.3%
0.0%
2.9%
68.6%
8.6%
2.9%
48.6%
11.4%
2.9%
97.1%
0.0%
2.9%
37.1%
17.1%
2.9%
94.3%
0.0%
5.7%
85.7%
2.9%
8.6%
88.6%
2.9%
2.9%
71.4%
11.4%
5.7%
71.4%
11.4%
5.7%
71.4%
17.1%
2.9%
94.3%
0.0%
5.7%

Median
2
2
1
1
1
2
2
1
1
1
1
1
1
1
1
1
1
1
1
2
1
1
1
1
2
1
1
1
1
1
1
1

AFTER DIET CHANGE
None
Always
No
(1)
(5)
Answer
40.0%
2.9%
5.7%
37.1%
0.0%
5.7%
88.6%
0.0%
11.4%
54.3%
0.0%
5.7%
48.6%
0.0%
5.7%
45.7%
0.0%
5.7%
28.6%
0.0%
5.7%
82.9%
2.9%
5.7%
71.4%
0.0%
8.6%
71.4%
2.9%
8.6%
88.6%
0.0%
5.7%
80.0%
0.0%
5.7%
62.9%
0.0%
5.7%
77.1%
2.9%
5.7%
57.1%
0.0%
5.7%
68.6%
11.4%
5.7%
88.6%
0.0%
8.6%
82.9%
0.0%
14.3%
48.6%
2.9%
5.7%
45.7%
5.7%
5.7%
94.3%
0.0%
5.7%
62.9%
2.9%
20.0%
60.0%
0.0%
5.7%
94.3%
0.0%
5.7%
40.0%
2.9%
5.7%
91.4%
0.0%
5.7%
85.7%
0.0%
11.4%
82.9%
2.9%
8.6%
62.9%
5.7%
20.0%
77.1%
14.3%
8.6%
95.7%
11.4%
11.4%
91.4%
0.0%
8.6%

60.0%

5.7%

20.0%

1

62.9%

2.9%

5.7%

45.8%
48.6%
77.1%
34.3%
77.1%
88.6%

20.0%
14.3%
5.7%
22.9%
11.4%
2.9%

2.9%
2.9%
11.4%
2.9%
2.9%
8.6%

2
1
1
2
1
1

45.7%
62.9%
80.0%
42.9%
74.3%
82.9%

0.0%
2.9%
2.9%
5.7%
2.9%
2.9%

5.7%
5.7%
14.3%
5.7%
5.7%
14.3%
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vitamin deficiencies

1.5

45.7%

11.4%

8.6%

1

62.9%

0.0%

Table 16. A summary of reported symptoms and their severity for participants, “before
diagnosis” and “after diet change.” 1= “none”, 2= “A little of the time”, 3= “some of the time”,
4- “most of the time”, 5= “all of the time”.
Qualitative Analysis
Two participants left additional comments regarding the effect of their diet change:

“Anemia and other lab work connected to GF diet. Also osteopenia improved.”
“Changed diet immediately because I had felt so bad- worked miracles going off
wheat/gluten items.” (P143A)
Comorbidity
The results for comorbid conditions are summarized in Table 17 below and include approximate
age at diagnosis for participants and number of affected family members per condition. Six
participants did not fill out the comorbid conditions portion of the survey (for their own
conditions). The most commonly reported conditions were: iron deficiency anemia (n=15),
autoimmune thyroid disease (n=8), and constipation, depression and lactose intolerance (each
n=8). Five participants each reported high blood pressure and inflammatory arthritis. Four
persons each listed eczema, fibromyalgia, nervous stomach and irritable bowel syndrome. Iron
deficiency anemia and autoimmune thyroid disease were diagnosed across wide age ranges: 1260 years and 10-49 years, respectively.

Autoimmune thyroid disorders and high blood pressure were the two most common conditions
listed for family members (13 each). Type-II diabetes was indicated for 12 family members total.

14.3%
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Condition
Iron Deficiency Anemia
Autoimmune Thyroid Disease
Constipation
Depression
lactose Intolerance
High Blood pressure
Inflammatory Arthritis
Eczema
Fibromyalgia
Irritable Bowel Syndrome
Nervous Stomach
Infertility (multiple
miscarriages)
Addison Disease
Raynaud's Disease
Pernicious Anemia
Rheumatoid Arthritis
Autoimmune Hepatitis
Cerebellar Ataxia
Colon Cancer
Grave's Disease
Polycystic Ovary Disease
Primary Sclerosing Cholangitis
Psoriasis
Type II Diabetes
Vitiligo
Atrophic Gastritis
Behcet Disease
Crohn's Disease
Dermatomyositis
Hardening of the arteries
Lupus
Multiple Sclerosis
Myasthenia Gravis
Non-Hodgkins Lymphoma
Chronic Liver Disease
Seizures
Sjogren Disease
Small Intestinal Cancer
Type I Diabetes Mellitus

Affected
Participants

Affected Family
Members

8
7
7
7
5
5
4
4
4
4

Age at Diagnosis
12, 14, 15, 18, 20, 23, 25, 27,
30, 30, 40, 49, 50, 56, 60
10, 30, 30, 33, 36, 40, 49
?, 3, 15, 18, 20, 49, 50
?, 14, 20, 30, 35, 36, 50
?, 30, 36, 37, 55, 56, 60
25, 30, 49, 59, 61
40, 40, 48, 50, 57
0, 14, 18, 40
21, 40, 40, 55
?, 30, 40, 50
?, 7, 10, 42

13
9
10
7
13
1
6
7
9
7

3

25, 25, 35

4

2
2
2
2
1
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0

49, 49
?, 51
45, 60
?, 12
10
61
53
30
16
61
40
65
20
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a

3
4
2
9
3
1
8
0
5
2
3
12
2
2
2
4
2
5
4
5
2
2
2
4
2
5
3

n= 15

n=7
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Table 17: Comorbid Conditions reported by participants. Approximate age at diagnosis is given
where known for the participant. Number of affected family members is listed for each
condition. Family includes mother, father, brother, sister, grandparents, children, and
grandchildren.
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DISCUSSION
Several factors that contribute to delayed diagnosis were identified within this study: confusion over
terminology, issues with symptom classification, a need for further training of medical professionals and
increased patient-doctor communication, and also low public awareness.

SAMPLE
The sample is a mostly older and well-educated group and clearly represents only a subset of individuals
affected by gluten-averse conditions.

TERMINOLOGY AND CLASSIFICATION
Terminology and corresponding definitions direct both research and diagnosis of various conditions,
creating and reinforcing the boundaries of ‘disease’. Currently, medical research supports the existence
of three gluten-averse conditions: gluten allergy, Celiac Disease, and non-Celiac gluten sensitivity. The
division of delayed onset gluten-averse symptomology into CD and NCGS belies a much more
complicated scenario, especially since CD clearly encompasses a broad spectrum of phenotypes.
Continued grouping of CD into ‘classic’ and ‘non-classic’ (or any other binary system) will only hinder the
research process of those who would seek to better understand such a complex disease and will
continue to result in a decreased quality of life for those who are denied diagnoses based on outdated
constructions of disease typology. As of 2011, NCGS stands to break from CD in to its own diagnostic
category based on recent findings (Sapone et al 2011) and it is unclear how much of the ‘non-classical’
manifestations it will take with it. NCGS needs to be consistently recognized as a clinical entity by
medical professionals. The very least of evidence for its existence should be in the presence of
numerous support groups across the U.S. (and other countries) that have formed geared toward
persons with “gluten intolerance”. This ‘third category’ of gluten-averse reactions (NCGS) is clearly one
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of the most misunderstood conditions- not merely for the lack of research into it as its own condition
(described later), but also because the terms used to describe it are inaccurate and are also used to
describe the other two gluten-averse conditions.
The impact of “typical CD” resulted in delayed diagnosis for at least one individual in the sample
(P26), whose doctor found histological evidence for CD (“gold standard”) but did not make the diagnosis
due to lack of diarrhea, weight-loss, and other ‘typical’ symptoms.

CD Spectrum
Persons diagnosed with CD in this study showed a mix of phenotypes- mostly ‘classic’. For example, P24
was diagnosed within the same year as ‘classic’ symptoms presented: abdominal distension, pain,
steatorrhea, diarrhea, failure to thrive, and chronic fatigue. Blood testing showed elevated EMA and
presence of anti-tTG. One was diagnosed with CD after an endoscopy/biopsy that was ‘looking for
something else’ (P47). Their listed symptoms included esophageal reflux, canker sores, some
constipation, and ‘mucus in bowels’. No timeline to diagnosis could be provided for this person as they
seem to exhibit “silent” CD.

NCGS as a Clinical Entity
Persons diagnosed with NCGS reported timelines to diagnosis that were more than 2 times as long as
those for persons with CD. This is undoubtedly related to a general lack of clinical recognition of NCGS
as a condition. Participant P68 eventually self-diagnosed after negative blood-test results and positive
response to a gluten-free diet after 28 years of chronic constipation. Participant P34 was not diagnosed
with ‘gluten intolerance’ for 16 years despite a previously diagnosed younger brother, and seeing both a
naturopath and gastroenterologist since a hospitalization. (All blood tests came back negative and the
participant did not have genetic markers for CD). Participant P112 visited 10 different medical
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professionals over a period of 22 years leading up to diagnosis as ‘gluten intolerant.’ This patient also
reported an increase in many symptoms post- diet change that might be indicative of a refractory state.
One patient reported undergoing 3 colonoscopies, an ultrasound, MRI and various urine, blood, stool
and saliva tests prior to visiting a naturopath for diagnosis with ‘gluten intolerance’ (P14).
The necessity of a paradigm shift in understanding CD (and NCGS) clinical manifestation
(definition) cannot be understated. Any further categorization of symptomology in these (and other)
conditions must be carefully constructed to avoid missed diagnoses. The lack of defined condition for
NCGS has undoubtedly delayed or prevented diagnoses for many and limited the pursuit of research
into NCGS as its own condition- much as the long-standing characterization of CD as a gastrointestinal
disorder has delayed acknowledgement of the full CD spectrum.
Combatting the confusion over these conditions must start with the development of clear and
consistent terminology, as well as the recognition of the full spectrum of conditions (including NCGS).
Further misguided use of terms will only continue to delay the relevant diagnoses that need to be made
for persons affected by these conditions. It should also be acknowledged that our labeling is subject to
change upon new information. In the future, the CD spectrum may well split into definably separate
conditions. However, it is this author’s opinion that medical professionals and researchers seeking cut
and dry etiologic explanations will not find it given the complexity of human physiology. A single disease
phenotype may have many underlying developmental pathways and the medical research arena is only
just beginning to appreciate the vast complexity of interactions between commensal bacteria and
humans, which is just one of the likely contributors to gluten-averse conditions.

Continued Training for Medical Professionals
The diagnostic trajectories described by patients in this study indicate that many medical professionals
are making CD diagnoses in good time frame: Patient P24 saw a dermatologist for skin condition that
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was diagnoses as dermatitis herpetiformis. The patient was subsequently sent to a gastroenterologist
for blood testing for CD. P29 saw a gynecologist who expressed concern about the patient’s osteopenia
and was referred back to their general practitioner. The GP performed both blood testing and
endoscopy and diagnosed the patient with CD.
However, presentation of ‘classic’ CD did not lead to reliably faster diagnoses. It is possible that
some of this delay might be accounted for by a lack of training/knowledge in previous decades and
some results may be more indicative of improved training for doctors. For P26, an upper endoscopy in
search for the cause of heartburn (in 1980) showed possible Celiac. Twenty years later a
gastroenterologist performed a blood test and confirmed presence of auto-antibodies. One of the most
delayed diagnoses was for a woman who had gastrointestinal symptoms since the 1970s and had visited
many doctors. In 2006, a general practitioner checked for CD and found that she had genetic risk
markers, and positive serology. Additionally, she had a younger brother who was diagnosed with CD at
age 2.
Participant P1’s delay in diagnosis however was the result of a current common misdiagnosis: “I
always had GI problems in high school, told me it was IBS.” This patient displayed all the common
markers of ‘classic’ CD and also test positive for CD autoantibodies and presence of intestinal damage.
P32 was sent to a gastroenterologist after constant diarrhea, bloating, and lots of gas. The
gastroenterologist performed a colonoscopy but did not look for CD nor have any serological testing
done. The patient subsequently saw an internist who ordered blood testing for CD, the results of which
were positive.
Timeline to diagnosis was calculated based on self-reported initial presenting symptoms. If
timeline to diagnosis took in to account the presence of common comorbid conditions, diagnosis length
might be greatly increased for many patients in this study: P150A was diagnosed with iron deficiency
anemia 9 years prior to diagnosis as “off the charts” CD. P143A also presented with iron deficiency, 3
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years prior to CD diagnosis. Patient P70 was diagnosed with depression at age 20, eczema from ages 1830, rheumatoid arthritis and had 4 miscarriages prior to diagnosis with CD at age 47. This would
increase time to diagnosis from 2 to 27 years. Time to diagnosis for P61 could be extended to 36 years
(from 20) if their reported diagnoses of eczema at age 14, iron deficiency anemia at 12, and nervous
stomach at age 7 were physiologically related to CD. Of course the connections for these patients will
never be verified. However, it should be taken as a reminder that highly variable symptomology, taken
even without overt CD, should prompt medical professionals to rule out gluten-averse conditions.
Furthermore, differentiation between CD and NCGS age at onset for different age groups is problematic
because date of diagnosis cannot be reliably tied to actual onset.
Naturally, it is recommended that medical professionals continue to receive training per the
most recent research on diagnostic procedure and interpretation of results.

Doctor-Patient Communication
Receptiveness to patient complaints and mutual participation in the diagnostic process are important in
improving quality of life. The results of this survey indicate the following several doctor-patient
communication items as opportunities for decreasing time to diagnosis.

Clarity of Diagnosis and Diagnostic Process
One patient was confused as to her exact diagnosis: “Not clear during consultation. Dr. said stop eating
gluten” (P7). She also stated that her blood test showed ‘gluten intolerance’ and that her
endoscopy/biopsy was negative. One might assume that the blood test looked anti-gliadin antibodies.
Her diagnosis took place in 2009 when anti-gliadin tests had largely been abandoned in favor of more
sensitive and specific anti-gliadin and anti-tTG. She identified herself as ‘gluten intolerant’ and ‘allergy
to wheat’ though she may still qualify for diagnosis as part of the CD spectrum given her listed
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symptoms: abdominal pain, diarrhea, constipation, itchy skin rash. Diagnoses should be made clear and
associated complications explained thoroughly to aid the patient in taking steps toward initiation and
maintenance of a gluten-free diet.
Participant P52 reports diagnosis with ‘wheat allergy’ and while indicating (prior to diagnosis)
daily bouts of illness. The only improved symptom listed was flatulence. No testing was listed for this
patient. Given that wheat allergy is an IgE-mediated immune response, continual ingestion would likely
have resulted in extreme physical reactions. One participant indicated that they were ‘probably Celiac’
because of their dermatitis herpetiformis but definitely ‘gluten intolerant’ (P61). They are most likely
‘definitely’ Celiac since DH is the well-documented cutaneous version of CD.

Seriousness of Condition
Approximately 40-85% of CD persons stick to the strict gluten free diet required by diagnosis (Ciacci et al
2002; Hogberg et al 2003). The fact that complications of CD are at least partly correlated with poor diet
adherence means that doctors need to stress the importance of diet change in the treatment of the
condition. Diagnosis with CD, NCGS, or GA need to be taken seriously by those affected. Persons
affected by GA are much less likely to ingest gluten except on accident due to the immediate physical
reaction. Delayed onset conditions should be taken just as seriously. The first step in emphasizing the
seriousness of the condition is clarity of diagnosis.

Self-Diagnosis
Some patients pursue diagnosis entirely on their own such as P16A, who self-diagnosed as ‘gluten
sensitive’ based on “personal reading”. Such situations highlight several things: (1) Clear, consistent and
accurate information for these conditions must to be available to the public. (2) Some persons may be
reluctant to trust medical professionals with help in diagnosis.
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Testing Family Members
The diagnosis of a family member should prompt a quicker screening and diagnosis for relatives than
what is observed in this sample. In some cases there was a lengthy delay in the diagnosis of the
participant after a family member had been diagnosed. Others reported that family members were
reluctant to pursue testing for one reason or another. Given the genetic associations of this condition,
diagnosis of a family member should spur testing for other family members.
Cases exist where a person is diagnosed and there is a subsequent string of diagnoses in the
family, as for P17, (6 family members of four generations). Whether this was medical or family initiative
is not provided by the respondent. In other cases, there is a large time lapse in diagnoses between
family members. It is possible that these individuals may have had an increased quality of life if they
had been diagnosed shortly after their family member:

“I self-diagnosed because my sister was diagnosed 20 years before me and I began having classic
symptoms” (P16). (Remember that some of the classic symptoms are associated with
destruction of the small intestine, a step that is not required for diagnosis in the CD spectrum).

Patient P34 “ended up in the hospital” before getting diagnosed as ‘gluten intolerant’. Her
diagnosis was delayed by approximately 16 years despite having a younger brother diagnosed
prior.

P36, was diagnosed as CD after approximately 31 years at age 65 (positive blood test and
histology). Her brother was diagnosed at age 2. Her current symptom list before and after diet
change may indicate a refractory state: not a single item is listed as improved and some of them
appear to increase post-diet change.
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In one case, a patient reports that when her sister was diagnosed with CD, she requested the doctor to
test her as well and was denied (P42).

Open Dialogue
Currently, clinical diagnosis by general practitioners and many other specialists is exclusively focused on
laboratory testing and medical interpretation of results. The spectrum of gluten-averse conditions has a
broad array of symptomology and a ‘big picture’ view of patient symptomology may assist in diagnosis.
Consequently, open discussion between medical professionals and patients should be encouraged.
Current understanding of the CD spectrum strongly suggests that a continued reliance on serological
and endoscopic tests alone will fail to catch numerous phenotypes. Furthermore, given that the best
current model for pathogenesis involves ‘multiple hits’ and that environmental triggers may vary
between individuals, it could be recommended that clinicians take in to account things such as NSAID
consumption, recent or repeated bacterial infections, and stress when determining if a patient might
benefit from a gluten free diet. To this end, open dialogue should be encouraged.

Increased Quality of Life and Avoiding Complications
Delayed diagnosis is significantly correlated with increased risk for complications and development of
refractory conditions in CD. The need for quicker diagnoses is further underwritten by the work of Biagi
and Corazza (2010) who suggest that the differences in mortality between populations with similar CD
prevalence may relate to gluten consumption levels prior to diagnosis. Persons with gluten-averse
conditions need to be diagnosed as quickly as possible to experience the increased quality in life
associated with diet change.
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Increased Public Awareness
Given the delay in onset and associated symptomology, it is likely that many individuals (1) either do not
suspect diet a factor in various illness (however mild) and/or (2) see certain ‘mild’ ailments (such as
headache, depression, etcetera) as normal and not deserving of medical attention (and corresponding
diet change). The sample described here represents a group who is very proactive about their own
health. Diagnoses to NCGS were markedly longer than that for CD, which is understandable given that
research evidence for NCGS as its own condition surfaced just this year. The patients here who
continually pursued NCGS diagnosis may not be typical of the population in general. Thus, one could
easily speculate a sizable number of the US population suffering needlessly from various avoidable
symptoms. Note that 1% of the United States population alone is equal to approximately 3 million
people.
The need for accurate information available to the public must also be emphasized.
Misinformation about gluten-averse conditions will only continue to self-perpetuate and delay
diagnoses.

Possible Mass-Screening
CD has been described as a ‘hidden epidemic’ (Green and Jones 2006) and fulfills recommended criteria
of the World Health Organization (WHO) for mass screening (1967): CD is an important health problem
for which there is a reliable treatment (gluten free diet). Medical facilities are available for mass
screening. A latent stage of the disease has been shown to exist and the natural history of CD is fairly
well understood (especially relative to other autoimmune conditions). The cost of early diagnosis and
treatment is cheaper than the treatment of the long term health effects that result from continued
symptomology, development of comorbid conditions and disease complications. Green et al (2008)
tracked cost of care for several cohorts over a period of 5 years: A group with newly diagnosed CD, and
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one group each of persons without diagnosis but who displayed 1, 2 or 3 CD-associated
symptoms/conditions. Relative value based medical costs (RVU) were calculated for the four groups and
it was found that “direct standardized medical costs” were 24—33% lower for the CD relative to Control
group 1, 24-38% lower than compared with control group 2, and 31-38% lower than those for control
group 3 (p <0.05, p<0.05, p<0.01, respectively). Cost discrepancy is attributed to less spent on office
visits, laboratory work, as well as various diagnostic, imaging and endoscopy/biopsy procedures.
A large multicenter study of CD by Fasano et al (2003) noted that physicians and/or insurance
companies would not pay for intestinal biopsies in approximately 21% of patients who had positive EMA
serology. The justification was that the costs of the procedure were not warranted given the symptoms.
Such a situation underscores a gross widespread misunderstanding of the serious condition and also
hinders diagnostic procedures for patients who rely on insurance, in cases where doctors are willing to
do an endoscopy. In such cases, doctors are limited by the insurance coverage of their patient. Current
average national cost for an endoscopy and biopsy is approximately $2700 (New Health Choice 2010).
Minimally, more routine blood testing for food allergy and auto-antigens is recommended for
family members of persons with gluten-averse symptoms and perhaps all who exhibit any of the
autoimmune disorders that are typically over represented in the families of CD patients.
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CONCLUSIONS
Delayed diagnoses in the spectrum of gluten-averse conditions may be reduced through the following:
(1) Standardization of terminology and definitions of CD, NCGS, and GA, with acknowledged
tentativeness that some of these labels may be revised as new research becomes available. Suggestions
for standardization have been put forth here. (2) Continued and more widespread acceptance of CD as
a spectrum for which previous diagnostic standards are inadequate. Negative serology and endoscopies
should not halt diagnosis toward gluten-averse conditions. (3) Recognition of NCGS as a clinical entity.
(4) Continued training for medical professionals in recognizing and diagnosing these conditions. (5)
Improvements in doctor-patient communication with special attention to clarity of diagnosis,
involvement of the patient in the diagnostic process, emphasis on the seriousness of the condition and
need for strict gluten-free diet adherence. (6) Increase in frequency of testing for family members and
other high risk populations (such as persons with autoimmune disorders). (7) An increase in public
awareness and appreciation of these conditions are medical entities; reliable and accurate publicly
available information for gluten-averse conditions. (8) Consideration of mass screening, which has been
effective in several European countries.
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